image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
c45122e8cce2c4f2b9195209cd589f573953f527ce96a31313375513fd67c2a1.png | simple | <table><tr><td>Group (n = 5)</td><td>Tumor volume(mm<sup>3</sup>)</td><td>Inhibitory Rate (%)</td><td>Tumor weight (g)</td><td>Inhibitory Rate (%)</td></tr><tr><td>control</td><td>2531.78 ± 153.25</td><td></td><td>1.194 ± 0.10</td><td></td></tr><tr><td>Tet (40 mg/kg)</td><td>1243.00 ± 55.19<sup>***</sup>... | <table><tr><td>Group (n = 5)</td><td>Tumor volume(mm3)</td><td>Inhibitory Rate (%)</td><td>Tumor weight (g)</td><td>Inhibitory Rate (%)</td></tr><tr><td>control</td><td>2531.78 ± 153.25</td><td></td><td>1.194 ± 0.10</td><td></td></tr><tr><td>Tet (40 mg/kg)</td><td>1243.00 ± 55.19***</td><td>50.90</td><td>0.641 ± 0.06**... | <table><tr><td>Group (n = 5)</td><td>Tumor volume(mm3)</td><td>Inhibitory Rate (%)</td><td>Tumor weight (g)</td><td>Inhibitory Rate (%)</td></tr><tr><td>Tet(120 mg/kg)</td><td>493.06 ± 145.63***</td><td>80.52</td><td>0.298 ± 0.09***</td><td>75.04</td></tr></table> |
de21fc2f4baca285a5b63fd8e109eb793b2b39ed9d4a807a8f7b583614004899.png | complex | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">Base case (male, female)</td><td>Age 55 years</td><td>Age 60 years</td></tr><tr><td>Threshold</td><td>Threshold</td></tr><tr><td>First aseptic revision rate (early)</td><td>1.31%, 1.13%</td><td>Robust</td><td>Robust</td></tr><tr><td>First aseptic revision rate (l... | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">Base case (male, female)</td></tr><tr></tr><tr><td>First aseptic revision rate (early)</td><td>1.31%, 1.13%</td></tr><tr><td>First aseptic revision rate (late)</td><td>0.61%, 0.63%</td></tr><tr><td>First infection revision rate (early)</td><td>0.20%, 0.17%</td></... | <table><tr><td>Age 55 years</td><td>Age 60 years</td></tr><tr><td>Threshold</td><td>Threshold</td></tr><tr><td>Robust</td><td>Robust</td></tr><tr><td>Robust</td><td>Robust</td></tr><tr><td>Robust</td><td>Robust</td></tr><tr><td>Robust</td><td>Robust</td></tr><tr><td>Robust</td><td>Robust</td></tr><tr><td>USD 123,700 (f... |
0d5dbbf57c60ff479fb1dc1cca048a73f524b079a64cc00f9b2a5bd210dfebb0.png | complex | <table><tr><td>Characteristics</td><td>Mean (SD)</td><td>n (%)</td></tr><tr><td colspan="3">Gender</td></tr><tr><td>Male</td><td></td><td>162 (47.5)</td></tr><tr><td>Female</td><td></td><td>179 (52.5)</td></tr><tr><td colspan="3">Marital Status</td></tr><tr><td>Single</td><td></td><td>20 (5.9)</td></tr><tr><td>Married<... | <table><tr><td>Characteristics</td><td>Mean (SD)</td><td>n (%)</td></tr></table> | <table><tr><td colspan="3">Gender</td></tr><tr><td>Male</td><td></td><td>162 (47.5)</td></tr><tr><td>Female</td><td></td><td>179 (52.5)</td></tr><tr><td colspan="3">Marital Status</td></tr><tr><td>Single</td><td></td><td>20 (5.9)</td></tr><tr><td>Married</td><td></td><td>257 (75.3)</td></tr><tr><td>Others</td><td></td>... |
ce5a487e1faf94a0498cdd4b3602a0369c4d73c7ada352958214bc768a537ea3.png | simple | <table><tr><td>Filtering Criteria</td><td>Number of SNPs Excluded</td><td>Number of SNPs Remaining</td></tr><tr><td>None</td><td>0</td><td>2,740,205</td></tr><tr><td>Multiple Variants hits</td><td>33,917</td><td>2,706,288</td></tr><tr><td>Heterozygous and Bias*</td><td>2,111,439</td><td>594,849</td></tr><tr><td>Flankin... | <table><tr><td>Filtering Criteria</td><td>Number of SNPs Excluded</td><td>Number of SNPs Remaining</td></tr><tr><td>None</td><td>0</td><td>2,740,205</td></tr></table> | <table><tr><td>Multiple Variants hits</td><td>33,917</td><td>2,706,288</td></tr><tr><td>Heterozygous and Bias*</td><td>2,111,439</td><td>594,849</td></tr><tr><td>Flanking Sequence**</td><td>5,482</td><td>589,367</td></tr><tr><td>Candidate SNPs</td><td></td><td>589,367</td></tr></table> |
2889fdaf2c346e44d545495d875e259a9faf162b6d7fde02adb4e4eb691d16b0.png | complex | <table><tr><td></td><td>Total cost</td><td>Medical cost</td><td>Drug cost</td></tr><tr><td colspan="4"><i>Crude cost change – binary indicator</i></td></tr><tr><td> Chronic users</td><td>20,161**(18,775–21,547)</td><td>10,925**(9637–12,213)</td><td>9236**(8841–9632)</td></tr><tr><td> Concomitant... | <table><tr><td></td><td>Total cost</td><td>Medical cost</td><td>Drug cost</td></tr><tr><td colspan="4">Crude cost change – binary indicator</td></tr><tr><td>Chronic users</td><td>20,161**(18,775–21,547)</td><td>10,925**(9637–12,213)</td><td>9236**(8841–9632)</td></tr><tr><td>Concomitant users</td><td>16,666**(15,893–17... | <table><tr><td></td><td>Total cost</td><td>Medical cost</td><td>Drug cost</td></tr><tr><td>Concomitant users</td><td>637*(134–1140)</td><td>-1036**(−1518 to −553)</td><td>1673**(1546–1799)</td></tr><tr><td>Opioid disorder</td><td>1558**(1039–2076)</td><td>671**(161–1181)</td><td>887**(809–964)</td></tr><tr><td colspan=... |
c5adf3bcf69d65954db1cbd728582c9325992429f537879df0918c8f5fa1ba9a.png | complex | <table><tr><td></td><td colspan="2">Patients with dementia N = 1059</td><td colspan="2">Comparison patients N = 5543</td></tr><tr><td>Non-Osteoporosis group</td><td>N</td><td>%</td><td>N.</td><td>%</td></tr><tr><td>Total</td><td></td><td></td><td></td><td></td></tr><tr><td>Non-osteoporosis</td><td>177</td><td>16.71</td... | <table><tr><td></td><td>Patients with dementia N = 1059</td></tr><tr><td>Non-Osteoporosis group</td><td>N</td></tr><tr><td>Total</td><td></td></tr><tr><td>Non-osteoporosis</td><td>177</td></tr><tr><td>Crude HR (95% CI)</td><td>1.36 (1.15- 1.60)*</td></tr><tr><td>Adjusted HR (95% CI)</td><td>1.35 (1.11- 1.64)*</td></tr>... | <table><tr><td>Patients with dementia N = 1059</td><td colspan="2">Comparison patients N = 5543</td></tr><tr><td>%</td><td>N.</td><td>%</td></tr><tr><td></td><td></td><td></td></tr><tr><td>16.71</td><td>768</td><td>13.86</td></tr><tr><td>1.36 (1.15- 1.60)*</td><td colspan="2">1.00</td></tr><tr><td>1.35 (1.11- 1.64)*</t... |
0cb2651a358636b72adb787701a911dc31c6f53fd0a80e7c585d99c71c4be044.png | complex | <table><tr><td>Congenital Malformation</td><td colspan="5">Count of Exposures</td></tr><tr><td></td><td>Number of dyads</td><td colspan="2">Fathers (max/individual = 3)</td><td colspan="2">Mothers (max/individual = 2)</td></tr><tr><td></td><td></td><td>Cases</td><td>Controls</td><td>Cases</td><td>Controls</td></tr><tr>... | <table><tr><td>Congenital Malformation</td><td colspan="5">Count of Exposures</td></tr><tr><td></td><td>Number of dyads</td><td colspan="2">Fathers (max/individual = 3)</td><td colspan="2">Mothers (max/individual = 2)</td></tr></table> | <table><tr><td></td><td></td><td>Cases</td><td>Controls</td><td>Cases</td><td>Controls</td></tr><tr><td>Multifactorial conditions with morphologic anomalies (excluding hip)</td><td>97</td><td>42</td><td>27</td><td>23</td><td>20</td></tr><tr><td>Hip dysplasia and dislocation</td><td>20</td><td>16</td><td>4</td><td>13</t... |
d7da4b6798480578b76f467e6850b59e9b9edb9879fd62c5d1975fd9c0ce81e5.png | simple | <table><tr><td>Cancer type</td><td>Mechanism</td><td>Agent</td><td>Phase</td></tr><tr><td>Melanoma</td><td>Anti-CTLA-4</td><td>Ipilimumab</td><td>FDA approved</td></tr><tr><td>Melanoma</td><td>Anti-PD-1</td><td>Nivolumab</td><td>Phase III</td></tr><tr><td>Melanoma</td><td>Anti-PD-1</td><td>Pembrolizumab</td><td>FDA app... | <table><tr><td>Cancer type</td><td>Mechanism</td><td>Agent</td><td>Phase</td></tr><tr><td>Melanoma</td><td>Anti-CTLA-4</td><td>Ipilimumab</td><td>FDA approved</td></tr><tr><td>Melanoma</td><td>Anti-PD-1</td><td>Nivolumab</td><td>Phase III</td></tr><tr><td>Melanoma</td><td>Anti-PD-1</td><td>Pembrolizumab</td><td>FDA app... | <table><tr><td>Cancer type</td><td>Mechanism</td><td>Agent</td><td>Phase</td></tr><tr><td></td><td>ne</td><td></td><td>ases I-II</td></tr><tr><td>NSCLC</td><td>Peptide vaccine</td><td>EGFR peptide</td><td>Phase III</td></tr><tr><td>NSCLC</td><td>Anti-CTLA-4</td><td>Ipilimumab</td><td>Phase III</td></tr><tr><td>NSCLC</t... |
25057fe7d785b93fcdba090dab02521fb9b5040a11fca9ba875e01cc21f18f55.png | simple | <table><tr><td>Item</td><td>Never</td><td>Seldom (< 1/month)</td><td>Occasionally (1 to 3 times/month)</td><td>Often (1 to 2 times/week)</td><td>Frequently (≥3 times/week)</td></tr><tr><td></td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Applied to patient care</td><td>0 ... | <table><tr><td>Item</td><td>Never</td><td>Seldom (< 1/month)</td><td>Occasionally (1 to 3 times/month)</td><td>Often (1 to 2 times/week)</td><td>Frequently (≥3 times/week)</td></tr><tr><td></td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr></table> | <table><tr><td>Applied to patient care</td><td>0 (0)</td><td>3 (14)</td><td>7 (33)</td><td>8 (38)</td><td>3 (14)</td></tr><tr><td>Reinforced by senior residents and faculty</td><td>0 (0)</td><td>4 (19)</td><td>12 (57)</td><td>5 (24)</td><td>0 (0)</td></tr></table> |
48ee398c87dd426524e19b1057848187b1288f4f147b30d140c621880c4929b5.png | simple | <table><tr><td>Drug</td><td>Target</td><td>Rat study standard findings</td><td>Human clinical findings</td><td>MMtox prediction</td></tr><tr><td>Captopril</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes (∗)</td></tr><tr><td>Lisinopril</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes (∗)</td></tr><tr><t... | <table><tr><td>Drug</td><td>Target</td><td>Rat study standard findings</td><td>Human clinical findings</td><td>MMtox prediction</td></tr><tr><td>Captopril</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes (∗)</td></tr><tr><td>Lisinopril</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes (∗)</td></tr><tr><td>Cyclospori... | <table><tr><td>Drug</td><td>Target</td><td>Rat study standard findings</td><td>Human clinical findings</td><td>MMtox prediction</td></tr><tr><td>Phenytoin</td><td>Kidney</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Captopril</td><td>Liver</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Cyclosporin A</td><td>Li... |
bfbdbe365487b672e94af3baa627f765decfa2814e6473b20e23653a9a0fe661.png | simple | <table><tr><td>Test Material/Chemical</td><td>Experimental Model</td><td>Findings</td><td>Reference</td></tr><tr><td>Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil)</td><td>Mouse 3T3-L1 preadipocytes</td><td>↓ accumulation of lipid droplets in adipocytes;↓ protein levels of key adipogenesi... | <table><tr><td>Test Material/Chemical</td><td>Experimental Model</td><td>Findings</td><td>Reference</td></tr><tr><td>Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil)</td><td>Mouse 3T3-L1 preadipocytes</td><td>↓ accumulation of lipid droplets in adipocytes;↓ protein levels of key adipogenesis transcript... | <table><tr><td>Fucoxanthin (pure chemical)</td><td>Mouse</td><td>↓ IL-1β, TNF-α, iNOS, and COX-2, and suppressed maleic dialdehyde (MDA) and infiltration of polymorphonuclear cells (PMN)</td><td>[47]</td></tr><tr><td>Petalonia binghamiae extract containing fucoxanthin</td><td>Mouse</td><td>↓ body weight gain, adipose t... |
a83e195256a896610895f7e6174c004113236875c1245549e5684f63170d3ad6.png | simple | <table><tr><td>Variable</td><td>HR* (95% CI)</td><td>p value </td></tr><tr><td>Age </td><td>1.04 (1.01–1.07)</td><td>0.014</td></tr><tr><td>Loss of Hemoglobin</td><td>1.23 (1.03–1.47)</td><td>0.023</td></tr><tr><td>Biopsy proven rejection</td><td>2.4 (1.41–4.0)</td><td>0.001</td></tr></table> | <table><tr><td>Variable</td><td>HR* (95% CI)</td><td>p value</td></tr></table> | <table><tr><td>Age</td><td>1.04 (1.01–1.07)</td><td>0.014</td></tr><tr><td>Loss of Hemoglobin</td><td>1.23 (1.03–1.47)</td><td>0.023</td></tr><tr><td>Biopsy proven rejection</td><td>2.4 (1.41–4.0)</td><td>0.001</td></tr></table> |
1fcba135271590b192a139f71668f35cc0d54a02e0170551e546335dde6712d6.png | simple | <table><tr><td>Scale</td><td>Measures</td></tr><tr><td>Physical Component</td><td></td></tr><tr><td> Physical functioning (PF)</td><td>Limitations in physical activities due to health problems</td></tr><tr><td> Role-physical (RP)</td><td>Limitations in usual daily activities due to health problems</td></tr><tr><td> Bod... | <table><tr><td>Scale</td></tr><tr><td>Physical Component</td></tr><tr><td>Physical functioning (PF)</td></tr><tr><td>Role-physical (RP)</td></tr><tr><td>Bodily pain (BP)</td></tr><tr><td>General health (GH)</td></tr><tr><td>Vitality (VT)</td></tr><tr><td>Mental Component</td></tr><tr><td>Social functioning (SF)</td></t... | <table><tr><td>Measures</td></tr><tr><td></td></tr><tr><td>Limitations in physical activities due to health problems</td></tr><tr><td>Limitations in usual daily activities due to health problems</td></tr><tr><td>Pain experienced due to health problems</td></tr><tr><td>General health perceptions</td></tr><tr><td>Self-pe... |
2b31d19b9dbfc2b5b6a8f7cb34b81bcee9d6b9943eab1d0e6e5810f4e4d9fdfd.png | complex | <table><tr><td rowspan="2">Risk factors</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>HR</td><td>p-value</td><td>95% CI</td><td>HR</td><td>p-value</td><td>95% CI</td></tr><tr><td>Lucat1 expression</td><td>1.155</td><td>0.000<sup>**</sup></td><td>1.082-1.233</td><td>1... | <table><tr><td rowspan="2">Risk factors</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>HR</td><td>p-value</td><td>95% CI</td><td>HR</td><td>p-value</td><td>95% CI</td></tr></table> | <table><tr><td>Lucat1 expression</td><td>1.155</td><td>0.000**</td><td>1.082-1.233</td><td>1.124</td><td>0.002**</td><td>1.043-1.211</td></tr><tr><td>Age</td><td>1.695</td><td>0.002**</td><td>1.220-2.354</td><td>1.488</td><td>0.018*</td><td>1.070-2.070</td></tr><tr><td>Grade</td><td>2.421</td><td>0.000**</td><td>1.692-... |
2da33c0d2fd2ee2094ea12853f89f2a96aaed83978c550d4685036a9bf45f3a8.png | simple | <table><tr><td>Parameters</td><td>Proposed Sensor </td><td>XTE-190</td></tr><tr><td>Operational mode</td><td>Absolute</td><td>Absolute</td></tr><tr><td>Pressure range</td><td>2 MPa</td><td>1.7 MPa</td></tr><tr><td>Compensated temperature range</td><td>+20–220 °C</td><td>+25–232 °C</td></tr><tr><td... | <table><tr><td>Parameters</td><td>Proposed Sensor</td><td>XTE-190</td></tr></table> | <table><tr><td>Operational mode</td><td>Absolute</td><td>Absolute</td></tr><tr><td>Pressure range</td><td>2 MPa</td><td>1.7 MPa</td></tr><tr><td>Compensated temperature range</td><td>+20–220 °C</td><td>+25–232 °C</td></tr><tr><td>Sensitivity (10 V power supply)</td><td>210 mV/100 kPa</td><td>8 mV/100 kPa</td></tr><tr><... |
52fc3b955005ff7269d2d43dd37f0cb10d7f3c3c8496acfe11a1d5ce0dd0390a.png | simple | <table><tr><td>Syntax Score Category</td><td>Low(<22)(n=83)</td><td>Intermediate(23-32)(n=36)</td><td>High(>32) p(n=21)</td><td> p </td></tr><tr><td>Age (years), <i>mean</i><i>Minimum-Maximum</i><i>95% CI</i></td><td>65.843-97(63.6-67.9)</td><td>70.346-87(66.8-73.8)</td><td>66.9 47-83(62.8-71.1)</td><td>0.074</td... | <table><tr><td>Syntax Score Category</td><td>Low(<22)(n=83)</td></tr><tr><td>Age (years), meanMinimum-Maximum95% CI</td><td>65.843-97(63.6-67.9)</td></tr><tr><td>Sex (male)</td><td>77 (92.77%)</td></tr><tr><td>Smoker</td><td>32 (38.55%)</td></tr><tr><td>Hyperlipidemia</td><td>47 (56.62%)</td></tr><tr><td>Hypertension</... | <table><tr><td>Intermediate(23-32)(n=36)</td><td>High(>32) p(n=21)</td><td>p</td></tr><tr><td>70.346-87(66.8-73.8)</td><td>66.9 47-83(62.8-71.1)</td><td>0.074</td></tr><tr><td>32 (88.89%)</td><td>21 (100%)</td><td>0.291</td></tr><tr><td>10 (27.77%)</td><td>8 (38.1%)</td><td>0.514</td></tr><tr><td>28 (77.78%)</td><td>8 ... |
b56014be0943a2b3573052caacdb23b880fb89f256771c44bc4118af95184080.png | complex | <table><tr><td>Type of cells</td><td colspan="7">Bladder cancer cell line</td></tr><tr><td></td><td>T24</td><td>RT4</td><td>5637</td><td>SW780</td><td>UMUC3</td><td>HT1376</td><td>TSSCUP</td></tr><tr><td>Unsorted</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td... | <table><tr><td>Type of cells</td><td colspan="7">Bladder cancer cell line</td></tr><tr><td></td><td>T24</td><td>RT4</td><td>5637</td><td>SW780</td><td>UMUC3</td><td>HT1376</td><td>TSSCUP</td></tr></table> | <table><tr><td>Unsorted</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>CD44high</td><td>7/10</td><td>5/10</td><td>3/10</td><td>3/10</td><td>5/10</td><td>2/10</td><td>5/10</td></tr><tr><td>CD44low</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/1... |
854c5449537f03bd83bc493d68728c8ca6c566118946af74f8af3b2e15f1377e.png | complex | <table><tr><td colspan="3">Mechanical incremental steps compression</td></tr><tr><td>Compression factor</td><td>Intraparticle porosity</td><td>Voidage space</td></tr><tr><td>(λ)</td><td>(<i>ε</i><sub><i>p</i></sub>)</td><td>(<i>ε</i>)</td></tr><tr><td>0.00</td><td>0.63</td><td>0.41</td></tr><tr><td>0.02<... | <table><tr><td colspan="3">Mechanical incremental steps compression</td></tr><tr><td>Compression factor</td><td>Intraparticle porosity</td><td>Voidage space</td></tr><tr><td>(λ)</td><td>(εp)</td><td>(ε)</td></tr></table> | <table><tr><td>0.00</td><td>0.63</td><td>0.41</td></tr><tr><td>0.02</td><td>0.60</td><td>0.39</td></tr><tr><td>0.05</td><td>0.63</td><td>0.36</td></tr><tr><td>0.10</td><td>0.62</td><td>0.33</td></tr><tr><td>0.15</td><td>0.60</td><td>0.31</td></tr></table> |
aa6167aba51afa0f768c57d9b5131559bc245d9e68c39046fb5df9d67feb38f0.png | simple | <table><tr><td>Group</td><td>Treatment</td><td>Sham</td></tr><tr><td>Men/women (number of patients)</td><td>3/17</td><td>4/16</td></tr><tr><td>Age (years)</td><td>43.5 ± 11.07</td><td>43.55 ± 7.82</td></tr><tr><td>Headache history (years)</td><td>15.25 ± 8.37</td><td>18.75 ± 9.98</td></tr><tr><td>Ba... | <table><tr><td>Group</td><td>Treatment</td><td>Sham</td></tr><tr><td>Men/women (number of patients)</td><td>3/17</td><td>4/16</td></tr><tr><td>Age (years)</td><td>43.5 ± 11.07</td><td>43.55 ± 7.82</td></tr><tr><td>Headache history (years)</td><td>15.25 ± 8.37</td><td>18.75 ± 9.98</td></tr></table> | <table><tr><td>Baseline VAS</td><td>7.75 ± 0.96</td><td>7.45 ± 0.88</td></tr><tr><td>Baseline headache duration (days/month)</td><td>21.05 ± 3.36</td><td>19.65 ± 3.66</td></tr><tr><td>Baseline MIDAS score</td><td>63.05 ± 19.89</td><td>63.60 ± 16.59</td></tr></table> |
b3186c48379ed32a672f1943b75e779ae27c9fc4ea664b52c05712d468524edd.png | complex | <table><tr><td></td><td colspan="8">Furosemide</td><td colspan="8">Placebo</td></tr><tr><td></td><td colspan="4">PEFR</td><td colspan="4">FEV1.0</td><td colspan="4">PEFR</td><td colspan="4">FEV 1.0</td></tr><tr><td>Study (year)</td><td>Baseline airflow</td><td>SD</td><td>Post-treatment airflow</td><td>SD</td><td>Baseli... | <table><tr><td></td><td colspan="8">Furosemide</td><td colspan="8">Placebo</td></tr><tr><td></td><td colspan="4">PEFR</td><td colspan="4">FEV1.0</td><td colspan="4">PEFR</td><td colspan="4">FEV 1.0</td></tr><tr><td>Study (year)</td><td>Baseline airflow</td><td>SD</td><td>Post-treatment airflow</td><td>SD</td><td>Baseli... | <table><tr><td>González-Sánchez and colleagues, 2002 [4]</td><td>N/A</td><td>N/A</td><td>0.820</td><td>0.460</td><td>0.910</td><td>0.067</td><td>N/A</td><td>N/A</td><td>0.850</td><td>0.340</td><td>0.980</td><td>0.078</td><td></td><td></td><td></td><td></td></tr><tr><td>Nannini and colleagues, 1992 [1]</td><td>147</td... |
a89fb4e93a51ddd895e9a8b2a9f341cfbb7c4bc12fed90b7065fb8c78883dba5.png | complex | <table><tr><td rowspan="2">Determinants</td><td rowspan="2">Food-hygiene practice</td><td colspan="3">Diarrhea</td></tr><tr><td>%</td><td>Unadjusted OR (95% CI)</td><td>Adjusted<sup>a </sup>OR (95% CI)</td></tr><tr><td>All children</td><td>Poor</td><td>11</td><td>1.15 (0.51–2.60)</td><td>1.33 (0.57–3.14)</t... | <table><tr><td rowspan="2">Determinants</td><td rowspan="2">Food-hygiene practice</td><td colspan="3">Diarrhea</td></tr><tr><td>%</td><td>Unadjusted OR (95% CI)</td><td>Adjusteda OR (95% CI)</td></tr><tr><td>All children</td><td>Poor</td><td>11</td><td>1.15 (0.51–2.60)</td><td>1.33 (0.57–3.14)</td></tr><tr><td></td><td... | <table><tr><td rowspan="2">Determinants</td><td rowspan="2">Food-hygiene practice</td><td colspan="3">Diarrhea</td></tr><tr><td>%</td><td>Unadjusted OR (95% CI)</td><td>Adjusteda OR (95% CI)</td></tr><tr><td></td><td>ter</td><td></td><td></td><td>.00</td></tr><tr><td></td><td>p-value</td><td></td><td>0.73</td><td>0.51<... |
2f04d54bf72318b01443391a31610b1354f3fda883ae295771328c1da536d8f9.png | simple | <table><tr><td>MODEL</td><td>χ<sup>2</sup>/df</td><td>GFI</td><td>AGFI</td><td>NFI</td><td>IFI</td><td>CFI</td><td>RMR</td><td>RMSEA</td></tr><tr><td>Experience value</td><td>2.0-5.0</td><td>>0.90</td><td>>0.90</td><td>>0.90</td><td>>0.90</td><td>>0.90</td><td><0.10</td><td><0.08</td></tr><tr>... | <table><tr><td>MODEL</td><td>χ2/df</td><td>GFI</td><td>AGFI</td><td>NFI</td><td>IFI</td><td>CFI</td><td>RMR</td><td>RMSEA</td></tr><tr><td>Experience value</td><td>2.0-5.0</td><td>>0.90</td><td>>0.90</td><td>>0.90</td><td>>0.90</td><td>>0.90</td><td><0.10</td><td><0.08</td></tr><tr><td>Model RT(Total sample)</td><td>4.... | <table><tr><td>MODEL</td><td>χ2/df</td><td>GFI</td><td>AGFI</td><td>NFI</td><td>IFI</td><td>CFI</td><td>RMR</td><td>RMSEA</td></tr><tr><td>Model RW(Wuhan)</td><td>4.693</td><td>0.904</td><td>0.893</td><td>0.900</td><td>0.908</td><td>0.909</td><td>0.058</td><td>0.077</td></tr><tr><td>Model RS(Shiyan)</td><td>3.370</td><... |
43af0dc0dbd541fddc8df4911fc337fa2dbf38be8e9f3e2efd1a2ade1c2bd00a.png | complex | <table><tr><td></td><td></td><td colspan="2">Specific Production (μmol/min/mg)</td></tr><tr><td>Substrate</td><td>Product</td><td>Monohydroxy Fatty Acid</td><td>Dihydroxy Fatty Acid</td></tr><tr><td>Palmitoleic acid (16:1<sup>Δ9</sup><i><sup>Z</sup></i>)</td><td>8-HHME</td><td>9.6 ± 0.2</td><td>NA</td></... | <table><tr><td></td><td></td></tr><tr><td>Substrate</td><td>Product</td></tr><tr><td>Palmitoleic acid (16:1Δ9Z)</td><td>8-HHME</td></tr><tr><td>Oleic acid (18:1Δ9Z)</td><td>8-HOME</td></tr><tr><td>Linoleic acid (18:2Δ9Z,12Z)</td><td>8-HODE, 8,11-DiHODE</td></tr><tr><td>Conjugated linoleic acid (18:2Δ9E,12E)</td><td>NA<... | <table><tr><td colspan="2">Specific Production (μmol/min/mg)</td></tr><tr><td>Monohydroxy Fatty Acid</td><td>Dihydroxy Fatty Acid</td></tr><tr><td>9.6 ± 0.2</td><td>NA</td></tr><tr><td>9.0 ± 0.1</td><td>NA</td></tr><tr><td>10.8 ± 0.1</td><td>1.4 ± 0.0</td></tr><tr><td>NA</td><td>NA</td></tr><tr><td>14.9 ± 0.0</td><td>1... |
6ec913de21ab3dd18d891840b584b0469d1cf68de560f208865c987584c3d8a9.png | complex | <table><tr><td colspan="2">Up-Regulated Genes</td><td colspan="2">Down-Regulated Genes</td></tr><tr><td>Gene Symbol</td><td>Gene Name</td><td>Gene Symbol</td><td>Gene Name</td></tr><tr><td><i>APOLD1</i></td><td>Apolipoprotein L domain containing 1</td><td><i>AMD1</i></td><td>S-adenosylmethionine decarboxylase 1</td></t... | <table><tr><td colspan="2">Up-Regulated Genes</td><td colspan="2">Down-Regulated Genes</td></tr><tr><td>Gene Symbol</td><td>Gene Name</td><td>Gene Symbol</td><td>Gene Name</td></tr><tr><td>APOLD1</td><td>Apolipoprotein L domain containing 1</td><td>AMD1</td><td>S-adenosylmethionine decarboxylase 1</td></tr><tr><td>Atro... | <table><tr><td></td><td></td><td>NTF3</td><td>Neurotrophin 3</td></tr><tr><td></td><td></td><td>NXT1</td><td>NUTF-like export factor1</td></tr><tr><td></td><td></td><td>PAK1IP1</td><td>PAK1 interacting protein 1</td></tr><tr><td></td><td></td><td>PLAU</td><td>Plasminogen activator, urokinase</td></tr><tr><td></td><td><... |
91270071125c2ef42f20c89866e12102c2627dc42f444b95578836cdd8d4aaef.png | simple | <table><tr><td>Annotation</td><td>Figure 1A*</td><td><i>S. pneumoniae TIGR4</i></td><td><i>S. pneumoniae </i>G54</td><td><i>S. mitis B6</i></td><td><i>S. oralis Uo5</i></td><td><i>S. gordonii V288</i></td><td><i>S. sanguinis SK36</i></td></tr><tr><td>Regulator</td><td>1</td><td>SP1674</td><td>SPG1583</td><td>smi0612</t... | <table><tr><td>Annotation</td><td>Figure 1A*</td><td>S. pneumoniae TIGR4</td><td>S. pneumoniae G54</td><td>S. mitis B6</td><td>S. oralis Uo5</td><td>S. gordonii V288</td><td>S. sanguinis SK36</td></tr><tr><td>Regulator</td><td>1</td><td>SP1674</td><td>SPG1583</td><td>smi0612</td><td>SOR0560</td><td>SGO0127</td><td>SSA0... | <table><tr><td>hypothetical protein</td><td>7</td><td>SP1680</td><td>SPG1588</td><td>smi0606</td><td>SOR0555</td><td>-</td><td>-</td></tr><tr><td>satA ABC transporter permease</td><td>8</td><td>SP1681</td><td>SPG1589</td><td>smi0605</td><td>SOR0553</td><td>-</td><td>-</td></tr><tr><td>satB ABC transporter permease</td>... |
6a76394ab013a24dee75bf7487c8f3597c72a868c624f39384346856d7c1dcea.png | simple | <table><tr><td></td><td></td><td>Age (year)</td><td>BMI (kg/m<sup>2</sup>)</td><td>Size of Tumor (mm)</td><td>Number of Tumor</td></tr><tr><td>Urine HER2/neu</td><td>r</td><td>-0.014</td><td>-0.022</td><td>0.277</td><td>-0.057</td></tr><tr><td></td><td>p</td><td>0.897</td><td>0.843</td><td>0.068</td><td>0.711</td></tr>... | <table><tr><td></td><td></td><td>Age (year)</td><td>BMI (kg/m2)</td><td>Size of Tumor (mm)</td><td>Number of Tumor</td></tr><tr><td>Urine HER2/neu</td><td>r</td><td>-0.014</td><td>-0.022</td><td>0.277</td><td>-0.057</td></tr><tr><td></td><td>p</td><td>0.897</td><td>0.843</td><td>0.068</td><td>0.711</td></tr><tr><td>U</... | <table><tr><td></td><td></td><td>Age (year)</td><td>BMI (kg/m2)</td><td>Size of Tumor (mm)</td><td>Number of Tumor</td></tr><tr><td>rinary HER2/neu/ Urinary Creatinine</td><td>r</td><td>8</td><td>0.122</td><td>.108</td><td>0.070</td></tr><tr><td></td><td>p</td><td>0.105</td><td>0.269</td><td>0.483</td><td>0.649</td></t... |
07e7c484abf4f50640825879b15d51fd79dfb72e226f326489d32e83301a3e5b.png | complex | <table><tr><td>sRNA id</td><td>Start</td><td>End</td><td>Length(nucleotides)</td><td>Flanking gene id</td><td>Strand*</td><td>Expression pattern</td><td>Relative copy numbers</td><td colspan="2">Primers</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Start</td><td>End</td></tr><... | <table><tr><td>sRNA id</td><td>Start</td><td>End</td><td>Length(nucleotides)</td><td>Flanking gene id</td><td>Strand*</td><td>Expression pattern</td><td>Relative copy numbers</td><td colspan="2">Primers</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Start</td><td>End</td></tr><... | <table><tr><td>sRNA12</td><td>4790423</td><td>4791589</td><td>~1167</td><td>BC4864/BC4865</td><td><><</td><td>↓↑↓</td><td>19</td><td>4791428</td><td>4791487</td></tr><tr><td>sRNA13</td><td>3802805</td><td>3802907</td><td>~103</td><td>BC3824/BC3825</td><td><><</td><td>↓↑↓</td><td>16</td><td>38028445</td><td>3802904</td>... |
c75814f543e52b3d86271f20f77fa3c079ec3500f8baef4b62bc6194cad5c0da.png | simple | <table><tr><td>Cell line class</td><td>S:MI</td><td>S:MER</td><td>MER:MI</td><td>Significant predictive relationships</td></tr><tr><td>HMEC</td><td><0.0001**</td><td>0.006**</td><td>0.0120*</td><td>S→MER, MER→MI, and S→MI</td></tr><tr><td>BL</td><td>0.5996</td><td>0.5954</td><td>0.1659</td><td>N/A<... | <table><tr><td>Cell line class</td><td>S:MI</td><td>S:MER</td><td>MER:MI</td><td>Significant predictive relationships</td></tr></table> | <table><tr><td>HMEC</td><td><0.0001**</td><td>0.006**</td><td>0.0120*</td><td>S→MER, MER→MI, and S→MI</td></tr><tr><td>BL</td><td>0.5996</td><td>0.5954</td><td>0.1659</td><td>N/A</td></tr><tr><td>LumB</td><td>0.0041*</td><td>0.4769</td><td><0.0001**</td><td>MER→MI, S→MI</td></tr><tr><td>CL</td><td>0.4827</td><td>0.3758... |
32d76eaeff27e75b9bb4aa58e6fa7605d0c11a7c032260eedcb192c03cfa6363.png | simple | <table><tr><td></td><td>cluster α</td><td>hybrid</td><td>cluster β</td></tr><tr><td>Lineage 1</td><td>80</td><td>0</td><td>1</td></tr><tr><td>Lineage 2</td><td>22</td><td>7</td><td>82</td></tr></table> | <table><tr><td></td><td>cluster α</td><td>hybrid</td><td>cluster β</td></tr><tr><td>Lineage 1</td><td>80</td><td>0</td><td>1</td></tr></table> | <table><tr><td></td><td>cluster α</td><td>hybrid</td><td>cluster β</td></tr><tr><td>Lineage 2</td><td>22</td><td>7</td><td>82</td></tr></table> |
cd89c283517ebb078cf212b4a1373c7ef988a4539b92fad631c7faf16978ff40.png | simple | <table><tr><td>PCMP Samples</td><td>Sample 1#</td><td>Sample 2#</td><td>Sample 3#</td><td>Sample 4#</td><td>Sample 5#</td><td>Sample 6#</td><td>Sample 7#</td><td>Sample 8#</td><td>Sample 9#</td></tr><tr><td>AP percentage (%)</td><td>0</td><td>2.5</td><td>5</td><td>7.5</td><td>10</td><td>12.5</td><td>15</td><td>17.5</td... | <table><tr><td>PCMP Samples</td><td>Sample 1#</td><td>Sample 2#</td><td>Sample 3#</td><td>Sample 4#</td><td>Sample 5#</td><td>Sample 6#</td><td>Sample 7#</td><td>Sample 8#</td><td>Sample 9#</td></tr></table> | <table><tr><td>AP percentage (%)</td><td>0</td><td>2.5</td><td>5</td><td>7.5</td><td>10</td><td>12.5</td><td>15</td><td>17.5</td><td>20</td></tr><tr><td>Heat transfer coefficient (W/m2·K)</td><td>2.38</td><td>2.42</td><td>2.59</td><td>2.68</td><td>2.84</td><td>2.98</td><td>3.05</td><td>3.11</td><td>3.24</td></tr></tabl... |
56a07978eb75aeab525da5e6118328f87e1f85ced2d5a3c6488282185e26cb96.png | complex | <table><tr><td>Guliver coding System</td><td rowspan="2">Total sample</td><td rowspan="2">NL</td><td rowspan="2">IT</td><td rowspan="2">UK</td><td rowspan="2">BE</td></tr><tr><td>Category</td></tr><tr><td>Non-verbal behaviour</td><td>69.1</td><td>74.4</td><td>90.0</td><td>59.0</td><td>62.6</td></tr><tr><td>Structuring<... | <table><tr><td>Guliver coding System</td><td rowspan="2">Total sample</td><td rowspan="2">NL</td><td rowspan="2">IT</td><td rowspan="2">UK</td><td rowspan="2">BE</td></tr><tr><td>Category</td></tr><tr><td>Non-verbal behaviour</td><td>69.1</td><td>74.4</td><td>90.0</td><td>59.0</td><td>62.6</td></tr><tr><td>Structuring<... | <table><tr><td>Collecting information</td><td>74.8</td><td>81.7</td><td>89.4</td><td>63.5</td><td>69.5</td></tr><tr><td>Giving information</td><td>91.4</td><td>86.7</td><td>100</td><td>87.9</td><td>92.8</td></tr><tr><td>Providing solution</td><td>95.3</td><td>100</td><td>97.2</td><td>73.3</td><td>97.0</td></tr><tr><td>... |
1c4b91f2ae963a7bafdf907aca89697c2b42ff15ef60cd556040649351f8c51c.png | simple | <table><tr><td></td><td>Grade 1</td><td>Grade 2</td><td>Grade 3</td><td>Total</td></tr><tr><td>Group 1</td><td>18 (47.3%)</td><td>15 (39.5%)</td><td>5 (13.2%)</td><td>38</td></tr><tr><td>Group 2</td><td>16 (44.4%)</td><td>13 (36.1%)</td><td>7 (19.4%)</td><td>36</td></tr></table> | <table><tr><td></td><td>Grade 1</td><td>Grade 2</td><td>Grade 3</td><td>Total</td></tr></table> | <table><tr><td>Group 1</td><td>18 (47.3%)</td><td>15 (39.5%)</td><td>5 (13.2%)</td><td>38</td></tr><tr><td>Group 2</td><td>16 (44.4%)</td><td>13 (36.1%)</td><td>7 (19.4%)</td><td>36</td></tr></table> |
20123052d4310f72cb269ee6f60757e45cfec717b4f8565edf59a400e18f1403.png | complex | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Secondhand Smoke Exposure in Household (/None)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>1–2 Days</td><td>1.00</td><td>0.88̵... | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Secondhand Smoke Exposure in Household (/None)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>1–2 Days</td><td>1.00</td><td>0.88–1.14</td><... | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Mother</td><td>1.84</td><td>1.52–2.22</td><td>2.46</td><td>1.87–3.24</td></tr><tr><td>Siblings</td><td>2.07</td><td>1.83–2.35</td><td>2.49</td><td>2.... |
99c9829b3e807589228e0a478030ebbae3d35c57fc2aa0eda1ff6b9195848a5e.png | complex | <table><tr><td rowspan="3">Variable</td><td rowspan="2">Placebo (<i>n</i> = 25)</td><td colspan="6">Telotristat ethyl</td></tr><tr><td colspan="3">250 mg tid (<i>n</i> = 25)</td><td colspan="3">500 mg tid (<i>n</i> = 25)</td></tr><tr><td>Mean (s.d.)</td><td>Mean (s.d.)</td><td><i>P</i></td><td>95% CL</td><td>Mean (s.d.... | <table><tr><td rowspan="3">Variable</td><td rowspan="2">Placebo (n = 25)</td><td colspan="6">Telotristat ethyl</td></tr><tr><td colspan="3">250 mg tid (n = 25)</td><td colspan="3">500 mg tid (n = 25)</td></tr><tr><td>Mean (s.d.)</td><td>Mean (s.d.)</td><td>P</td><td>95% CL</td><td>Mean (s.d.)</td><td>P</td><td>95% CL</... | <table><tr><td colspan="8">Stool consistency</td></tr><tr><td>Change from baseline in stool consistency averaged over 12 weeks (Bristol Stool Form scale)</td><td>0.01 (0.41)</td><td>−0.20 (0.70)</td><td>–</td><td>–</td><td>−0.60 (0.86)</td><td>–</td><td>–</td></tr><tr><td>Arithmetic mean treatment difference</td><td>−<... |
f92cd5d011a2ef0b1071124804f603c29631d9a8d72005b4c22c7c16f1636a67.png | simple | <table><tr><td>Performance Statistics</td><td>Total(<i>n</i> = 1053)</td><td>Initial surgery-MR interval ≤ 36 months(<i>n</i> = 709)</td><td>Initial surgery-MR interval > 36 months(<i>n</i> = 344)</td><td><i>p</i> value</td></tr><tr><td>Cancer detection rate for MRI<sup>a</sup></td><td>6.7 (7/1053)</td><td>1.4... | <table><tr><td>Performance Statistics</td><td>Total(n = 1053)</td><td>Initial surgery-MR interval ≤ 36 months(n = 709)</td><td>Initial surgery-MR interval > 36 months(n = 344)</td><td>p value</td></tr><tr><td>Cancer detection rate for MRIa</td><td>6.7 (7/1053)</td><td>1.4 (1/709)</td><td>17.4 (6/344)</td><td>0.006</td>... | <table><tr><td>PPV1</td><td>4/76 (5.3%)</td><td>1/49 (2.0%)</td><td>3/27 (11.1%)</td><td>0.125</td></tr><tr><td>PPV3</td><td>3/19 (15.8%)</td><td>1/10 (10.0%)</td><td>2/9 (22.2%)</td><td>0.582</td></tr><tr><td>Sensitivity</td><td>3/4 (75.0%)</td><td>1/1 (100%)</td><td>2/3 (66.7%)</td><td>> 0.999</td></tr><tr><td>Specif... |
d2df24024962d4ecb7fc1034267c9387755e791ead3ad2984879ec05b7fe78ae.png | complex | <table><tr><td></td><td>Men</td><td>Women</td><td></td></tr><tr><td></td><td colspan="2">Change from baseline value</td><td><i>P</i> value</td></tr><tr><td>HR (beats/min)</td><td>47 ± 12</td><td>38 ± 10</td><td>0.20</td></tr><tr><td>MAP (mmHg)</td><td>−31 ± 9</td><td>−33 ± 8</td><td>0.45... | <table><tr><td></td><td>Men</td></tr><tr><td></td><td>Change from baseline value</td></tr><tr><td>HR (beats/min)</td><td>47 ± 12</td></tr><tr><td>MAP (mmHg)</td><td>−31 ± 9</td></tr><tr><td>SAP (mmHg)</td><td>−54 ± 7</td></tr><tr><td>DAP (mmHg)</td><td>−18 ± 5</td></tr><tr><td>SV (mL)</td><td>−57 ± 8</td></tr><tr><td>Q... | <table><tr><td>Women</td><td></td></tr><tr><td>Change from baseline value</td><td>P value</td></tr><tr><td>38 ± 10</td><td>0.20</td></tr><tr><td>−33 ± 8</td><td>0.45</td></tr><tr><td>−48 ± 8</td><td>0.29</td></tr><tr><td>−18 ± 7</td><td>0.78</td></tr><tr><td>−41 ± 4</td><td>0.006</td></tr><tr><td>−1.4 ± 0.4</td><td>0.3... |
8e298d72c64af258baa9af87aae515ec7961a4043e23b0974a05823bf2c48a92.png | simple | <table><tr><td>Gene Title and Abbreviation (The GENE Database)</td><td>Percent Change </td></tr><tr><td>OPRM1, 1 opioid receptor, mu 1</td><td>+1294</td></tr><tr><td>TP73, 2 tumor protein p73</td><td>+938</td></tr><tr><td>KCND1, 3 potassium voltage-gated channel, Shal-related subfamily, member 1</td><td>+845</td></tr><... | <table><tr><td>Gene Title and Abbreviation (The GENE Database)</td><td>Percent Change</td></tr><tr><td>OPRM1, 1 opioid receptor, mu 1</td><td>+1294</td></tr><tr><td>TP73, 2 tumor protein p73</td><td>+938</td></tr><tr><td>KCND1, 3 potassium voltage-gated channel, Shal-related subfamily, member 1</td><td>+845</td></tr><t... | <table><tr><td>Gene Title and Abbreviation (The GENE Database)</td><td>Percent Change</td></tr><tr><td>CHRM2, 230 cholinergic receptor, muscarinic 2</td><td>−1049</td></tr></table> |
073de18bfcab82ee45d5b27f77030bf99a6d86c8fcec4c50fcd3de10a51fc411.png | complex | <table><tr><td rowspan="2">Prognostic factor/parameter</td><td rowspan="2">N evt/N pts</td><td colspan="2">Univariate analysis (n=108)</td><td colspan="2">Multivariate analysis (n=99)</td></tr><tr><td>HR [95% CI]</td><td><i>p</i>-Value (Wald)</td><td>HR [95% CI]</td><td><i>p</i>-Value (Wald)</td></tr><tr><td>Smoker sta... | <table><tr><td rowspan="2">Prognostic factor/parameter</td><td rowspan="2">N evt/N pts</td><td colspan="2">Univariate analysis (n=108)</td><td colspan="2">Multivariate analysis (n=99)</td></tr><tr><td>HR [95% CI]</td><td>p-Value (Wald)</td><td>HR [95% CI]</td><td>p-Value (Wald)</td></tr><tr><td>Smoker status</td><td></... | <table><tr><td rowspan="2">Prognostic factor/parameter</td><td rowspan="2">N evt/N pts</td><td colspan="2">Univariate analysis (n=108)</td><td colspan="2">Multivariate analysis (n=99)</td></tr><tr><td>HR [95% CI]</td><td>p-Value (Wald)</td><td>HR [95% CI]</td><td>p-Value (Wald)</td></tr><tr><td>Coarse (2.8)</td><td></t... |
8e5e8afeff06649aa22209969495d941eb7f46392f243ce483971cc866d9b803.png | complex | <table><tr><td></td><td></td><td colspan="5">Relative risk reduction</td></tr><tr><td></td><td></td><td>20%</td><td>24%</td><td>28%</td><td>32%</td><td>35%</td></tr><tr><td>Control event rate</td><td>25%</td><td>0.49</td><td>0.68</td><td>0.84</td><td>0.93</td><td>0.97</td></tr><tr><td></td><td>27%</td><td>0.54</td><td>... | <table><tr><td></td><td></td><td>Relative risk reduction</td></tr><tr><td></td><td></td><td>20%</td></tr><tr><td>Control event rate</td><td>25%</td><td>0.49</td></tr><tr><td></td><td>27%</td><td>0.54</td></tr><tr><td></td><td>30%</td><td>0.61</td></tr><tr><td></td><td>33%</td><td>0.68</td></tr><tr><td></td><td>35%</td>... | <table><tr><td colspan="4">Relative risk reduction</td></tr><tr><td>24%</td><td>28%</td><td>32%</td><td>35%</td></tr><tr><td>0.68</td><td>0.84</td><td>0.93</td><td>0.97</td></tr><tr><td>0.73</td><td>0.87</td><td>0.95</td><td>0.98</td></tr><tr><td>0.80</td><td>0.92</td><td>0.98</td><td>0.99</td></tr><tr><td>0.85</td><td... |
e463722e0d61154e0b10b52afa6eec580f0fc6f9a8a7aa29f0f63778d3acdd23.png | simple | <table><tr><td> </td><td>Predicted change in hazard for one unit change in variable</td><td>Significance (<i>P</i>)</td></tr><tr><td>HADS anxiety</td><td>1.012 (0.39–2.58)</td><td>0.98</td></tr><tr><td>HADS depression</td><td>0.82 (0.22–3.05)</td><td>0.76</td></tr><tr><td>PANAS negative affect</td><td>1.07 ... | <table><tr><td></td><td>Predicted change in hazard for one unit change in variable</td><td>Significance (P)</td></tr><tr><td>HADS anxiety</td><td>1.012 (0.39–2.58)</td><td>0.98</td></tr><tr><td>HADS depression</td><td>0.82 (0.22–3.05)</td><td>0.76</td></tr></table> | <table><tr><td></td><td>Predicted change in hazard for one unit change in variable</td><td>Significance (P)</td></tr><tr><td>PANAS negative affect</td><td>1.07 (0.33–3.47)</td><td>0.90</td></tr><tr><td>Mood rating scale</td><td>1.20 (0.48–3.0)</td><td>0.68</td></tr><tr><td>FACT C FW</td><td>0.56 (0.16–1.89)</td><td>0.8... |
6bddfae7be93ecfa85b7b28dd77ad2927644c8071c63bd48da8898650db1e5e9.png | simple | <table><tr><td> </td><td>N</td><td>Minimum</td><td>Maximum</td><td>Mean</td><td>Std. Deviation</td></tr><tr><td>IL- 17 B</td><td>24</td><td>18.258</td><td>31.605</td><td>23.63281</td><td>3.553243</td></tr><tr><td>IL-10 B</td><td>24</td><td>.00</td><td>112.43</td><td>13.8533</td><td>28.72131</td></tr><tr><td>IL-17 P</td... | <table><tr><td></td><td>N</td><td>Minimum</td><td>Maximum</td><td>Mean</td><td>Std. Deviation</td></tr><tr><td>IL- 17 B</td><td>24</td><td>18.258</td><td>31.605</td><td>23.63281</td><td>3.553243</td></tr><tr><td>IL-10 B</td><td>24</td><td>.00</td><td>112.43</td><td>13.8533</td><td>28.72131</td></tr><tr><td>IL-17 P</td>... | <table><tr><td>HCT</td><td>24</td><td>28.4</td><td>46.5</td><td>36.192</td><td>4.7277</td></tr><tr><td>PLT</td><td>24</td><td>87</td><td>658</td><td>283.71</td><td>117.411</td></tr><tr><td>HB</td><td>24</td><td>9</td><td>16</td><td>12.02</td><td>1.675</td></tr><tr><td>GR%</td><td>24</td><td>43.5</td><td>93.8</td><td>71... |
20a6135d7fa210053e50836a51f31cc37bec988b3ff31510821e29a02f5860ac.png | simple | <table><tr><td>Author, Year [Reference]</td><td>Study Design</td><td>StudyPopulationParticipantsAgeBMIHealth Status</td><td>Intervention and Doses</td><td>Duration Weeks</td><td>Observed Effects</td></tr><tr><td>Pol, 2013 [28]</td><td>Meta-analysis of 26 RCTs</td><td>2060 M/F18–70 years18.5–35.8 kg/m<sup>2<... | <table><tr><td>Author, Year [Reference]</td><td>Study Design</td><td>StudyPopulationParticipantsAgeBMIHealth Status</td><td>Intervention and Doses</td><td>Duration Weeks</td><td>Observed Effects</td></tr><tr><td>Pol, 2013 [28]</td><td>Meta-analysis of 26 RCTs</td><td>2060 M/F18–70 years18.5–35.8 kg/m2Healthy</td><td>Wh... | <table><tr><td>Kim, 2016 [29]</td><td>Meta-analysis of 21 RCTs</td><td>940 M/F47–57 years27.6–31.4 kg/m2Metabolic syndrome</td><td>Dietary pulses (mean dose: 142 g/day)vs. control</td><td>4–12</td><td>↓ BW: −0.34 kgvs.control</td></tr><tr><td>Mytton, 2014 [30]</td><td>Meta-analysis of 8 RCTs</td><td>1026 M/F30–75 years... |
01948ae250c97faaf24303c7d359e2314a9e1d1246d5543bb168ad3037a5f85e.png | simple | <table><tr><td>Year</td><td>High-risk owned dogs</td><td>Pets</td></tr><tr><td></td><td>Positive/Total (%)</td><td>Positive/Total (%)</td></tr><tr><td>2011</td><td>7/196 (3.6)</td><td>8/811 (1.0)</td></tr><tr><td>2012</td><td>10/502 (2.0)</td><td>9/561 (1.6)</td></tr><tr><td>2013</td><td>10/415 (2.4)</td><td>–</t... | <table><tr><td>Year</td><td>High-risk owned dogs</td><td>Pets</td></tr><tr><td></td><td>Positive/Total (%)</td><td>Positive/Total (%)</td></tr><tr><td>2011</td><td>7/196 (3.6)</td><td>8/811 (1.0)</td></tr><tr><td>2012</td><td>10/502 (2.0)</td><td>9/561 (1.6)</td></tr><tr><td></td><td>10/415</td><td>–</td></tr></table> | <table><tr><td>Year</td><td>High-risk owned dogs</td><td>Pets</td></tr><tr><td></td><td>Positive/Total (%)</td><td>Positive/Total (%)</td></tr><tr><td>2013</td><td> (2.4)</td><td></td></tr><tr><td>2014</td><td>3/209 (1.4)</td><td>–</td></tr><tr><td>2015</td><td>4/200 (2.0)</td><td>–</td></tr><tr><td>2016</td><td>3/200 ... |
a112902abfbe0ebc2adcae64cfa2bf09ca52e21f20b1a682ea67d996dbb8cc0b.png | complex | <table><tr><td>Assembler</td><td>Number of scaffolds</td><td>Longest scaffold (kb)</td><td>Longest scaffold corr. (kb)</td><td>N50 (kb)</td><td>Err.</td><td>N50 corr. (kb)</td><td>LAP</td></tr><tr><td colspan="8"><i>Human chromosome 14</i>, starting from Velvet assembly</td></tr><tr><td> Before</td><td>1,081</td><td>4,... | <table><tr><td>Assembler</td><td>Number of scaffolds</td><td>Longest scaffold (kb)</td><td>Longest scaffold corr. (kb)</td></tr><tr><td colspan="4">Human chromosome 14, starting from Velvet assembly</td></tr><tr><td>Before</td><td>1,081</td><td>4,628</td><td>263</td></tr><tr><td>After</td><td>1,634</td><td>1,046</td><t... | <table><tr><td>N50 (kb)</td><td>Err.</td><td>N50 corr. (kb)</td><td>LAP</td></tr><tr><td colspan="4">Human chromosome 14, starting from Velvet assembly</td></tr><tr><td>1,190</td><td>9,156</td><td>27</td><td>−138.765779</td></tr><tr><td>347</td><td>8,049</td><td>27</td><td>−138.632657</td></tr><tr><td>36</td><td>4,607<... |
0c30c092c376aefc9f2daee32d3e146163d61bf02fd6cfe6593927d71e9b102d.png | complex | <table><tr><td></td><td>*1/*1 (n<i> </i>=<i> </i>229)</td><td>*1/*2 + *2/*2 (n<i> </i>=<i> </i>148)</td><td><i>P</i>‐value</td></tr><tr><td>Lesion vessel number</td><td></td><td></td><td>NS</td></tr><tr><td>1 (n, %)</td><td>55 (24%)</td><td>39 (26.4%)</td><td></td></tr><tr><td>2 (n, %)</td><td>69 (30.1%)</td><td>... | <table><tr><td></td><td>*1/*1 (n = 229)</td><td>*1/*2 + *2/*2 (n = 148)</td><td>P‐value</td></tr><tr><td>Lesion vessel number</td><td></td><td></td><td>NS</td></tr><tr><td>1 (n, %)</td><td>55 (24%)</td><td>39 (26.4%)</td><td></td></tr><tr><td>2 (n, %)</td><td>69 (30.1%)</td><td>43 (29.1%)</td><td></td></tr></table> | <table><tr><td></td><td>*1/*1 (n = 229)</td><td>*1/*2 + *2/*2 (n = 148)</td><td>P‐value</td></tr><tr><td>3 (n, %)</td><td>105 (45.9%)</td><td>66 (44.6%)</td><td></td></tr><tr><td colspan="4">Lesion vessel</td></tr><tr><td>LM (n, %)</td><td>23 (10%)</td><td>27 (18.2%)</td><td>.033</td></tr><tr><td>LAD (n, %)</td><td>184... |
585dfeabbbc24436b2d00e138a97dc781b3588696f202abd6affc92c29f11e39.png | simple | <table><tr><td>Variable</td><td>Possible score range</td><td>Group</td><td>Number</td><td>Baseline Mean (SD)</td><td>Number</td><td>Month 3 Mean (SD)</td><td>Mean change (SD)</td><td><i>t</i>-test (<i>p</i>-value) <sup>a</sup></td></tr><tr><td>Self-management knowledge<sup>b</sup></td><td>0–27</td><td>Interventio... | <table><tr><td>Variable</td><td>Possible score range</td></tr><tr><td>Self-management knowledgeb</td><td>0–27</td></tr><tr><td></td><td></td></tr><tr><td>Self-efficacy for HF self-managementc</td><td>0–100</td></tr><tr><td></td><td></td></tr><tr><td>Patient activation (PAM Rasch scaled scores) d</td><td>0–100</td></tr>... | <table><tr><td>Group</td><td>Number</td><td>Baseline Mean (SD)</td><td>Number</td><td>Month 3 Mean (SD)</td><td>Mean change (SD)</td><td>t-test (p-value) a</td></tr><tr><td>Intervention</td><td>51</td><td>21.1 (2.8)</td><td>51</td><td>23.1 (2.7)</td><td>2.0 (3.4)</td><td>.337</td></tr><tr><td>Control</td><td>49</td><td... |
79e8eac811b2a1f5719e02ec70367f7e8ee136637cc51a752192f1fdc7f63dc8.png | complex | <table><tr><td>Repeat type</td><td colspan="3">Structured</td><td colspan="3">Unstructured</td></tr><tr><td></td><td>RONN</td><td>DISOPRED</td><td>IUPRED</td><td>RONN</td><td>DISOPRED</td><td>IUPRED</td></tr><tr><td>E</td><td>3</td><td>13</td><td>10</td><td>97</td><td>87</td><td>90</td></tr><tr><td>P</td><td>6</td><td>... | <table><tr><td>Repeat type</td></tr><tr><td></td></tr><tr><td>E</td></tr><tr><td>P</td></tr><tr><td>A</td></tr><tr><td>S</td></tr><tr><td>L</td></tr><tr><td>G</td></tr><tr><td>Q</td></tr></table> | <table><tr><td colspan="3">Structured</td><td colspan="3">Unstructured</td></tr><tr><td>RONN</td><td>DISOPRED</td><td>IUPRED</td><td>RONN</td><td>DISOPRED</td><td>IUPRED</td></tr><tr><td>3</td><td>13</td><td>10</td><td>97</td><td>87</td><td>90</td></tr><tr><td>6</td><td>5</td><td>5</td><td>94</td><td>95</td><td>95</td>... |
cf762ac10a009531ba1257fbd813396054efb756f18b4fa31ea0b86fbdab4662.png | complex | <table><tr><td></td><td>Setting</td><td colspan="6">Results of simulations</td></tr><tr><td>Methods (Effect measures)</td><td><i>β</i><sub>X</sub></td><td>Mean of estimates (Ratio scale)</td><td>Bias (Log scale)</td><td>Empirical standard error</td><td>Mean squared error</td><td>Mean standard error</td><td>Coverag... | <table><tr><td></td><td>Setting</td><td colspan="6">Results of simulations</td></tr></table> | <table><tr><td>Methods (Effect measures)</td><td>βX</td><td>Mean of estimates (Ratio scale)</td><td>Bias (Log scale)</td><td>Empirical standard error</td><td>Mean squared error</td><td>Mean standard error</td><td>Coverage (%)</td></tr><tr><td>SCCS (IRR)</td><td>log(1.0)</td><td>0.99</td><td>-0.0125</td><td>0.1354</td><... |
fda82e4d7263a1359ee3a36cd925dd498c0f2d17ff27a5e707fe0b09ad37df85.png | simple | <table><tr><td>mRNA</td><td>Primers<sup>a</sup></td></tr><tr><td>MMP-13</td><td>Fw: 5'-TTGGTCAGATGTGACACCTCRv: 5'-ATCGGGAAGCATAAAGTGGC</td></tr><tr><td>Cathepsin K</td><td>Fw: 5'-AGGTGGATGAAATCTCTCGGRv: 5'-TTCTTGAGTTGGCCCTCCAG</td></tr><tr><td>5-LOX</td><td>Fw: 5'-TGCGTTCCAGTGACTTCCACRv: 5'-CTCTGCACCATCTGCACGTG</td></t... | <table><tr><td>mRNA</td><td>Primersa</td></tr><tr><td>MMP-13</td><td>Fw: 5'-TTGGTCAGATGTGACACCTCRv: 5'-ATCGGGAAGCATAAAGTGGC</td></tr><tr><td>Cathepsin K</td><td>Fw: 5'-AGGTGGATGAAATCTCTCGGRv: 5'-TTCTTGAGTTGGCCCTCCAG</td></tr><tr><td>5-LOX</td><td>Fw: 5'-TGCGTTCCAGTGACTTCCACRv: 5'-CTCTGCACCATCTGCACGTG</td></tr><tr><td>A... | <table><tr><td>ADAMTS-5</td><td>Fw: 5'-GGCATCATTCATGTGACACRv: 5'-GCATCGTAGGTCTGTCCTG</td></tr><tr><td>GAPDH</td><td>Fw: 5'-AGGCTGTGGGCAAGGTCATCRv: 5'-AAGGTGGAAGAGTGGGTGTC</td></tr></table> |
86ea0e98ce038fc35fa42fa866b200ae597b4f2f6a616f97cbfa7adc4657a33c.png | simple | <table><tr><td>Population</td><td>GO ID</td><td>Gene ontology term</td><td>Genes under GO term</td><td>Related environmental stressor(s)</td><td>Reference</td></tr><tr><td>Kuroilers</td><td>GO:0060584</td><td>Regulation of prostaglandin-endoperoxide synthase activity</td><td>EDN2, EDN1</td><td>Oxidative stress/Pathogen... | <table><tr><td>Population</td><td>GO ID</td><td>Gene ontology term</td><td>Genes under GO term</td><td>Related environmental stressor(s)</td><td>Reference</td></tr><tr><td>Kuroilers</td><td>GO:0060584</td><td>Regulation of prostaglandin-endoperoxide synthase activity</td><td>EDN2, EDN1</td><td>Oxidative stress/Pathogen... | <table><tr><td>GO:0016627</td><td>Oxidoreductase activity, acting on the CH-CH group of donors</td><td>IVD, CPOX, ACAD9, DHCR24</td><td>Oxidative/Environmental Stress</td><td>UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89]</td></tr><tr><td>GO:0006950</td><td>Response to stress</td><td>ENTPD1, ETFDH, WNT5A CHID... |
b0a0ca8a28e28a04cb11345d10850bb389359be438496ced9bd1775966bc517f.png | simple | <table><tr><td>Source</td><td><i>F</i> ratio</td><td><i>p</i></td></tr><tr><td>Method</td><td>7.377</td><td>0.013</td></tr><tr><td>Method × group</td><td>0.373</td><td>0.547</td></tr><tr><td>Task</td><td>35.697</td><td>0.000</td></tr><tr><td>Task × group</td><td>0.030</td><td>0.865</td></tr><tr><td>Hemisphere... | <table><tr><td>Source</td><td>F ratio</td><td>p</td></tr><tr><td>Method</td><td>7.377</td><td>0.013</td></tr><tr><td>Method × group</td><td>0.373</td><td>0.547</td></tr><tr><td>Task</td><td>35.697</td><td>0.000</td></tr><tr><td>Task × group</td><td>0.030</td><td>0.865</td></tr><tr><td>Hemisphere</td><td>0.310</td><td>0... | <table><tr><td>Hemisphere × group</td><td>0.692</td><td>0.414</td></tr><tr><td>Method × task</td><td>4.838</td><td>0.039</td></tr><tr><td>Method × task × group</td><td>0.005</td><td>0.945</td></tr><tr><td>Method × hemisphere</td><td>0.047</td><td>0.831</td></tr><tr><td>Method × hemisphere × group</td><td>0.042</td><td>... |
2a30fa2f96392860b4f606ebe018f130370c2e15201d428a8221204f10570aa2.png | simple | <table><tr><td>Solvents</td><td>SC16-Lu</td><td>TC18-Lu</td><td>TC16-Lu</td><td>TC14-Lu</td><td>TC12-Lu</td></tr><tr><td>Acetone</td><td>I</td><td>I</td><td>G (1.5)</td><td>I</td><td>PS</td></tr><tr><td>Aniline</td><td>S</td><td>G (2.0)</td><td>G (2.0)</td><td>G (1.5)</td><td>PS</td></tr><tr><td>Toluene</td><td>PS</td>... | <table><tr><td>Solvents</td><td>SC16-Lu</td><td>TC18-Lu</td><td>TC16-Lu</td><td>TC14-Lu</td><td>TC12-Lu</td></tr><tr><td>Acetone</td><td>I</td><td>I</td><td>G (1.5)</td><td>I</td><td>PS</td></tr><tr><td>Aniline</td><td>S</td><td>G (2.0)</td><td>G (2.0)</td><td>G (1.5)</td><td>PS</td></tr><tr><td>Toluene</td><td>PS</td>... | <table><tr><td>Isopropanol</td><td>PS</td><td>G (2.5)</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Cyclopentanone</td><td>PS</td><td>G (2.0)</td><td>G (1.5)</td><td>PS</td><td>PS</td></tr><tr><td>Cyclohexanone</td><td>PS</td><td>PS</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Nitrobenzene</td><td>S<... |
237a23175dded2f1092b0704a81f7d577ff0b282fd4c554ca3e2ee4c50f9950f.png | complex | <table><tr><td> </td><td>Biocatalyst</td><td>S/B</td><td>RS%</td><td>Xyl%</td><td>Glc%</td><td>Useful results</td></tr><tr><td rowspan="2">1</td><td rowspan="2">TL-xylanase</td><td rowspan="2">3.3</td><td rowspan="2">23.5</td><td rowspan="2">2.26</td><td rowspan="2">8.6</td><td>xylobiose 3.3 g/L</td></tr><tr><td>pentas... | <table><tr><td></td><td>Biocatalyst</td><td>S/B</td><td>RS%</td><td>Xyl%</td><td>Glc%</td></tr><tr><td rowspan="2">1</td><td rowspan="2">TL-xylanase</td><td rowspan="2">3.3</td><td rowspan="2">23.5</td><td rowspan="2">2.26</td><td rowspan="2">8.6</td></tr><tr></tr><tr><td>2</td><td>TM-xylanase</td><td>2.6</td><td>38</t... | <table><tr><td>Useful results</td></tr><tr><td>xylobiose 3.3 g/L</td></tr><tr><td>pentasaccharide 1 (Figure 2), 2 g/L</td></tr><tr><td>-</td></tr><tr><td>-</td></tr><tr><td>-</td></tr><tr><td>tetrasaccharide 2 (Figure 2) 2.64 g/L</td></tr><tr><td>see Figure 3</td></tr><tr><td>see Figure 3</td></tr><tr><td>see Figure 3<... |
6a85f3b98cba0a627f1325dfb0b61309c1c29bb51a681a8472acf2782cf3ec27.png | complex | <table><tr><td></td><td>Reason for hysterectomy</td><td></td><td>Number of women with vaginal bleeding</td><td>Odds ratio (95% CI)</td></tr><tr><td rowspan="6">Supracervical abdominal hysterectomy</td><td rowspan="2">Fibroids</td><td>Yes</td><td>16</td><td>0.66 (0.16, 2.71)*</td></tr><tr><td>No</td><td>3</td><td></td><... | <table><tr><td></td><td>Reason for hysterectomy</td><td></td><td>Number of women with vaginal bleeding</td><td>Odds ratio (95% CI)</td></tr><tr><td rowspan="6">Supracervical abdominal hysterectomy</td><td rowspan="2">Fibroids</td><td>Yes</td><td>16</td><td>0.66 (0.16, 2.71)*</td></tr><tr><td>No</td><td>3</td><td></td><... | <table><tr><td></td><td>Reason for hysterectomy</td><td></td><td>Number of women with vaginal bleeding</td><td>Odds ratio (95% CI)</td></tr><tr><td rowspan="2">Supracervical laparoscopic hysterectomy</td><td rowspan="2">Pain and/or endometriosis</td><td>Yes</td><td>23</td><td>0.41 (0.20, 0.85)*</td></tr><tr><td>No</td>... |
fa25f3bc99b3f07260d9c69edcff8a5bd4c6c036271eaeccba439571587b2366.png | simple | <table><tr><td>Module</td><td>Module hub genes</td><td>Module membership</td><td>LPS log2FC</td><td>DE FDR</td></tr><tr><td>module I</td><td><i>BIRC3</i></td><td>0.97</td><td>1.26</td><td>1.89e-12</td></tr><tr><td>module I</td><td><i>VPS37A</i></td><td>0.95</td><td>0.53</td><td>3.97e-9</td></tr><tr><td>module I</td><td... | <table><tr><td>Module</td><td>Module hub genes</td><td>Module membership</td></tr><tr><td>module I</td><td>BIRC3</td><td>0.97</td></tr><tr><td>module I</td><td>VPS37A</td><td>0.95</td></tr><tr><td>module I</td><td>STARD13</td><td>0.94</td></tr><tr><td>module I</td><td>SOD2</td><td>0.94</td></tr><tr><td>module I</td><td... | <table><tr><td>LPS log2FC</td><td>DE FDR</td></tr><tr><td>1.26</td><td>1.89e-12</td></tr><tr><td>0.53</td><td>3.97e-9</td></tr><tr><td>0.80</td><td>1.01e-4</td></tr><tr><td>1.75</td><td>8.83e-16</td></tr><tr><td>2.83</td><td>3.62e-18</td></tr><tr><td>0.53</td><td>3.39e-8</td></tr><tr><td>0.84</td><td>5.30e-8</td></tr><... |
59af4aeaf7b6e182f31bf732260bdabf5b8f6a9632d4b9b1092bdbc32a5063be.png | simple | <table><tr><td>Comparator</td><td>Correlation [95% CI] with UCEIS</td><td>Correlation [95% CI] with Modified Baron Score<sup>a</sup></td></tr><tr><td>Full MCS<sup>+</sup> [including endoscopy]</td><td>0.86 [0.83, 0.88]</td><td>N/A<sup>b</sup></td></tr><tr><td>Partial MCS [excluding endoscopy]</td><td>0.82 [0.79, 0.85]<... | <table><tr><td>Comparator</td><td>Correlation [95% CI] with UCEIS</td><td>Correlation [95% CI] with Modified Baron Scorea</td></tr><tr><td>Full MCS+ [including endoscopy]</td><td>0.86 [0.83, 0.88]</td><td>N/Ab</td></tr></table> | <table><tr><td>Comparator</td><td>Correlation [95% CI] with UCEIS</td><td>Correlation [95% CI] with Modified Baron Scorea</td></tr><tr><td>Partial MCS [excluding endoscopy]</td><td>0.82 [0.79, 0.85]</td><td>0.77 [0.61, 0.88]</td></tr><tr><td>Stool frequency subscore</td><td>0.76 [0.72, 0.80]</td><td>0.73 [0.53, 0.85]</... |
55265840356d74c790ec41d061e9b8737e4e53ae1a35b01c85cc8dbb0ece513e.png | simple | <table><tr><td></td><td>Vials with FA detectedn (%)</td><td>Vials without FAn (%)</td></tr><tr><td>Infundibulae or surface structures on sections</td><td>376 (72.6)</td><td>94 (18.1)</td></tr><tr><td>No infundibulae or surface structures on sections</td><td>0 (0.0)</td><td>48 (9.3)</td></tr></table> | <table><tr><td></td><td>Vials with FA detectedn (%)</td><td>Vials without FAn (%)</td></tr></table> | <table><tr><td>Infundibulae or surface structures on sections</td><td>376 (72.6)</td><td>94 (18.1)</td></tr><tr><td>No infundibulae or surface structures on sections</td><td>0 (0.0)</td><td>48 (9.3)</td></tr></table> |
58a50a61712fb6bfd8738fb1156ef24cd39df3f1d86c8a8c589abda6d3e77a0e.png | complex | <table><tr><td rowspan="2">Image number</td><td colspan="3">Proposed method (<i>e</i><sub>1</sub>)</td><td colspan="3">Method proposed by Zhang (<i>e</i><sub>2</sub>)</td></tr><tr><td>7</td><td>14</td><td>20</td><td>7</td><td>14</td><td>20</td></tr><tr><td>1</td><td>0.050</td><td>0.021</td><td>0.011</td><td>0.041</td><... | <table><tr><td rowspan="2">Image number</td><td colspan="3">Proposed method (e1)</td><td colspan="3">Method proposed by Zhang (e2)</td></tr><tr><td>7</td><td>14</td><td>20</td><td>7</td><td>14</td><td>20</td></tr><tr><td>1</td><td>0.050</td><td>0.021</td><td>0.011</td><td>0.041</td><td>0.034</td><td>0.012</td></tr><tr>... | <table><tr><td>5</td><td>0.032</td><td>0.036</td><td>0.012</td><td>0.028</td><td>0.047</td><td>0.014</td></tr><tr><td>6</td><td>0.098</td><td>0.040</td><td>0.019</td><td>0.029</td><td>0.013</td><td>0.009</td></tr><tr><td>7</td><td>0.057</td><td>0.035</td><td>0.017</td><td>0.037</td><td>0.018</td><td>0.015</td></tr><tr>... |
551074ee442b4da02e38bad7a5d84f1ee6de4f446fa2b31d8604900c81356e38.png | simple | <table><tr><td>Variable</td><td>Number</td><td>%</td></tr><tr><td>Age, mean ± SD</td><td>69.0 ± 10.2</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td></tr><tr><td> Male</td><td>159</td><td>70.7</td></tr><tr><td> Female</td><td>66</td><td>29.3</td></tr><tr><td>Histology</td><td> </td><td> </td></tr><tr><... | <table><tr><td>Variable</td><td>Number</td><td>%</td></tr><tr><td>Age, mean ± SD</td><td>69.0 ± 10.2</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td>Male</td><td>159</td><td>70.7</td></tr><tr><td>Female</td><td>66</td><td>29.3</td></tr><tr><td>Histology</td><td></td><td></td></tr><tr><td>Adenocarcinoma... | <table><tr><td>Variable</td><td>Number</td><td>%</td></tr><tr><td>NSCLC-NOS</td><td>10</td><td>4.4</td></tr><tr><td>Pleomorphic</td><td>5</td><td>2.2</td></tr><tr><td>Adenosquamous</td><td>4</td><td>1.8</td></tr><tr><td>Pathological stage</td><td></td><td></td></tr><tr><td>IA</td><td>78</td><td>34.5</td></tr><tr><td>IB... |
bd4f98437065e6233f5ba62aeb94c828072e6abcac23bf38b3c52e1a55f9e132.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">Total population</td><td>Consumers only</td><td rowspan="2" colspan="3">Percentiles of intake among consumers</td></tr><tr><td colspan="2">N = 8,861</td><td>n = 2,310</td></tr><tr><td>Gender</td><td>Mean ± SE</td><td>Pct.</td><td>Mean ± SE</td><td>25th ± S... | <table><tr><td></td><td colspan="2">Total population</td><td>Consumers only</td><td colspan="3">Percentiles of intake among consumers</td></tr></table> | <table><tr><td></td><td colspan="2">N = 8,861</td><td>n = 2,310</td><td colspan="3">Percentiles of intake among consumers</td></tr><tr><td>Gender</td><td>Mean ± SE</td><td>Pct.</td><td>Mean ± SE</td><td>25th ± SE</td><td>50th ± SE</td><td>75th ± SE</td></tr><tr><td>Combined</td><td>50.3 ± 1.8</td><td>23.8</td><td>210.0... |
ee274ad530b54de04a371851dd62cbb79b7c09d58859f74c56aa2784f614c495.png | complex | <table><tr><td rowspan="2">Sample <sup>a</sup></td><td colspan="5">Molar Composition <sup>b</sup> (Relative %, mol/mol)</td><td colspan="2">Molar Ratio <sup>c</sup></td></tr><tr><td>Ara</td><td>Gal</td><td>Glc</td><td>Xyl</td><td>GlcA</td><td>GlcA/Xyl</td><td>Ara/Xyl</td></tr><tr><td>H<sub>2</sub></td><td>11.25 ± ... | <table><tr><td rowspan="2">Sample a</td><td colspan="5">Molar Composition b (Relative %, mol/mol)</td><td colspan="2">Molar Ratio c</td></tr><tr><td>Ara</td><td>Gal</td><td>Glc</td><td>Xyl</td><td>GlcA</td><td>GlcA/Xyl</td><td>Ara/Xyl</td></tr><tr><td>H2</td><td>11.25 ± 0.2</td><td>4.60 ± 0.1</td><td>22.01 ± 0.1</td><t... | <table><tr><td>H24</td><td>6.48 ± 0.1</td><td>0.59 ± 0.0</td><td>2.87 ± 0.2</td><td>86.93 ± 0.0</td><td>3.30 ± 0.0</td><td>0.03</td><td>0.07</td></tr></table> |
7c0b26e8fc87352967ca7fb189db6f12c2f889db8749aae5931b62a6cb3c8e56.png | complex | <table><tr><td>Microorganisms</td><td>Isolation Sites</td><td>Applications</td><td>Enzyme</td><td>Reference</td></tr><tr><td><i>Pseudoalteromonas haloplanktis</i></td><td>Antarctica</td><td>Starch conversion; detergent</td><td>Amylase Endo-amylase</td><td>[106]</td></tr><tr><td><i>Zunongwangia profunda</i></td><td>Deep... | <table><tr><td>Microorganisms</td><td>Isolation Sites</td><td>Applications</td><td>Enzyme</td><td>Reference</td></tr><tr><td>Pseudoalteromonas haloplanktis</td><td>Antarctica</td><td>Starch conversion; detergent</td><td>Amylase Endo-amylase</td><td>[106]</td></tr><tr><td>Zunongwangia profunda</td><td>Deep-sea, China</t... | <table><tr><td>Microorganisms</td><td>Isolation Sites</td><td>Applications</td><td>Enzyme</td><td>Reference</td></tr><tr><td>Martelella mediterranea</td><td>Lake Martel, Spain</td><td>cellulose conversion; detergent</td><td>Beta-glucosidase</td><td>[22]</td></tr><tr><td>Desulfotalea psychrophila</td><td>Marine sediment... |
c52942c59800e1e1458fc050a25d1076d68fd853687556befa2079deda66c754.png | simple | <table><tr><td>Indicator</td></tr><tr><td>A Ratio of native Dutch within total population: both parents were born in the Netherlands</td></tr><tr><td>B Ratio of Moroccan origin within total population: person or at least one parent was born in Morocco</td></tr><tr><td>C Ratio of Turkish origin within total population: ... | <table><tr><td>Indicator</td></tr><tr><td>A Ratio of native Dutch within total population: both parents were born in the Netherlands</td></tr><tr><td>B Ratio of Moroccan origin within total population: person or at least one parent was born in Morocco</td></tr><tr><td>C Ratio of Turkish origin within total population: ... | <table><tr><td>E Ratio of Antillean origin within total population: person or at least one parent was born in the Netherlands Antilles</td></tr></table> |
965a1204bfa8274f8aa00b0364e36fa0afa7cf10a225ba767755f42f4ddf02cd.png | simple | <table><tr><td></td><td>C</td><td>C + WGP</td><td>HF</td><td>HF + WGP</td></tr><tr><td>Glucose in plasma (mg/dL)</td><td>94.8 ± 1.8</td><td>88.3 ± 3.0</td><td>104.3 ± 2.8*</td><td>91. ± 2.84</td></tr><tr><td>Triglycerides in plasma (mg/mL)</td><td>92.4 ± 6.8</td><td>108.8 ± 4.2</td><td>140... | <table><tr><td></td><td>C</td><td>C + WGP</td><td>HF</td><td>HF + WGP</td></tr><tr><td>Glucose in plasma (mg/dL)</td><td>94.8 ± 1.8</td><td>88.3 ± 3.0</td><td>104.3 ± 2.8*</td><td>91. ± 2.84</td></tr><tr><td>Triglycerides in plasma (mg/mL)</td><td>92.4 ± 6.8</td><td>108.8 ± 4.2</td><td>140.7 ± 11.2*</td><td>122.1 ± 7.8... | <table><tr><td>terial pressure (mmHg)</td><td>± 4.4</td><td>6 ± 2.1</td><td>5.0 ± 1.7</td><td>1.8</td></tr><tr><td>Body weight (g)</td><td>515.8 ± 22.6</td><td>519.1 ± 17.9</td><td>514.0 ± 22.4</td><td>528.9 ± 21.8</td></tr><tr><td>Heart weight (g)</td><td>1.43 ± 0.05</td><td>1.46 ± 0.06</td><td>1.50 ± 0.05</td><td>1.5... |
81274611a5afc73b18c413e91bb9388a408184e4a0e45b78d874073f03a2ffe3.png | complex | <table><tr><td>Variable</td><td>Group on-pump (<i>n</i> = 146)</td><td>Group off-pump (<i>n</i> = 92)</td><td><i>P</i> Value</td></tr><tr><td colspan="4">Clinical demographics</td></tr><tr><td> Age (y)</td><td>65 ± 8</td><td>63 ± 9</td><td>0.0749</td></tr><tr><td> Female sex</td><td>25 (17.1%)</td><td>12(13.0... | <table><tr><td>Variable</td><td>Group on-pump (n = 146)</td><td>Group off-pump (n = 92)</td><td>P Value</td></tr><tr><td colspan="4">Clinical demographics</td></tr><tr><td>Age (y)</td><td>65 ± 8</td><td>63 ± 9</td><td>0.0749</td></tr><tr><td>Female sex</td><td>25 (17.1%)</td><td>12(13.0%)</td><td>0.398</td></tr><tr><td... | <table><tr><td>Variable</td><td>Group on-pump (n = 146)</td><td>Group off-pump (n = 92)</td><td>P Value</td></tr><tr><td>brovascular accident</td><td>.1%)</td><td>.1%)</td><td>.000</td></tr><tr><td>COPD</td><td>6(4.1%)</td><td>22(23.9%)</td><td>0.000</td></tr><tr><td>Calcified ascending aorta</td><td>4(2.7%)</td><td>45... |
ea05a163c528a5df64164aa77faff34999192099e3366825cf614106079e98a1.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>Total population</td></tr><tr><td>n = 3807</td></tr><tr><td colspan="2"><i>Gender</i></td></tr><tr><td>Male</td><td>42.1 %</td></tr><tr><td colspan="2"><i>Age (years)</i></td></tr><tr><td>Mean (SD)</td><td>78 (7.68)</td></tr><tr><td>Range</td><td>65–102</td></tr>... | <table><tr><td rowspan="2">Characteristics</td><td>Total population</td></tr><tr><td>n = 3807</td></tr><tr><td colspan="2">Gender</td></tr><tr><td>Male</td><td>42.1 %</td></tr><tr><td colspan="2">Age (years)</td></tr><tr><td>Mean (SD)</td><td>78 (7.68)</td></tr><tr><td>Range</td><td>65–102</td></tr><tr><td colspan="2">... | <table><tr><td>ange</td><td>26</td></tr></table> |
58a2797d5d03f854f208dd760699e1bd47f9be6ca55471894a18e25d379b5598.png | complex | <table><tr><td></td><td colspan="2">(-)crystal packing</td><td colspan="5">biological interactions(+)</td></tr><tr><td><i>support </i>level</td><td colspan="7">range of support ratios</td></tr><tr><td></td><td>-INF</td><td>-2</td><td>1</td><td>2</td><td>3</td><td>> = 4</td><td>INF</td></tr><tr><td></td><td>-INF</td>... | <table><tr><td></td><td colspan="2">(-)crystal packing</td><td colspan="5">biological interactions(+)</td></tr><tr><td>support level</td><td colspan="7">range of support ratios</td></tr><tr><td></td><td>-INF</td><td>-2</td><td>1</td><td>2</td><td>3</td><td>> = 4</td><td>INF</td></tr><tr><td></td><td>-INF</td><td>(-2.5,... | <table><tr><td>3</td><td>0</td><td>3</td><td>0</td><td>38</td><td>0</td><td>0</td><td>207</td></tr><tr><td>4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>13</td><td>0</td><td>40</td></tr><tr><td>> = 5</td><td>0</td><td>0</td><td>0</td><td>1</td><td>7</td><td>6</td><td>23</td></tr><tr><td>Total</td><td>13</td><td>3</... |
ddc696e49d9b5992c46b17678caa479643a03a5daa53e45eb47467be617f10fc.png | simple | <table><tr><td></td><td>Total group (n = 270)</td><td>Subgroup (n = 141)</td></tr><tr><td>Haemoglobin (g/dl)</td><td>13.1 ± 0.9</td><td>13.2 ± 0.9</td></tr><tr><td>Haematocrit (%)</td><td>39.2 ± 2.7</td><td>39.2 ± 2.8</td></tr><tr><td>Mean Corpuscular Volume (fl.)</td><td>87.2 ± 5.0</td><td>86.... | <table><tr><td></td><td>Total group (n = 270)</td><td>Subgroup (n = 141)</td></tr><tr><td>Haemoglobin (g/dl)</td><td>13.1 ± 0.9</td><td>13.2 ± 0.9</td></tr><tr><td>Haematocrit (%)</td><td>39.2 ± 2.7</td><td>39.2 ± 2.8</td></tr><tr><td>Mean Corpuscular Volume (fl.)</td><td>87.2 ± 5.0</td><td>86.9 ± 5.0</td></tr><tr><td>... | <table><tr><td>Serum iron (μg/dl)</td><td>81.7 ± 37.5</td><td>80.0 ± 36.</td></tr><tr><td>Transferrin saturation (%)</td><td>19.4 ± 10.2</td><td>18.8 ± 8.7</td></tr></table> |
97c04dff93eb76784078ded1b8bb8a3829687f91425a40324959203c28ab55c4.png | simple | <table><tr><td>Layers</td><td>Attacks</td></tr><tr><td>Physical layer</td><td>Jamming, Node tampering</td></tr><tr><td>Link layer/medium access control</td><td>Collision, exhaustion, and unfairness</td></tr><tr><td>Network and routing layer</td><td>Neglect and greed, homing, misdirection, spoofing, replaying, routing-c... | <table><tr><td>Layers</td></tr><tr><td>Physical layer</td></tr><tr><td>Link layer/medium access control</td></tr><tr><td>Network and routing layer</td></tr><tr><td>Transport layer</td></tr><tr><td>Application layer</td></tr></table> | <table><tr><td>Attacks</td></tr><tr><td>Jamming, Node tampering</td></tr><tr><td>Collision, exhaustion, and unfairness</td></tr><tr><td>Neglect and greed, homing, misdirection, spoofing, replaying, routing-control traffic or clustering messages</td></tr><tr><td>Flooding and De-synchronization</td></tr><tr><td>Overwhelm... |
d1f36bf7f7510d77cca26057d2ad87d6e41395e7bddd8b31e2e82777e549cac3.png | complex | <table><tr><td></td><td colspan="3">ADC: SUVmax</td><td colspan="3">SQC: SUVmax</td></tr><tr><td>Factor</td><td>Low</td><td>High</td><td><i>P</i>value</td><td>Low</td><td>High</td><td><i>P</i>value</td></tr><tr><td>Pleural invasion</td><td></td><td></td><td>0.027</td><td></td><td></td><td>0.064</td></tr><tr><td> No</td... | <table><tr><td></td><td colspan="3">ADC: SUVmax</td><td colspan="3">SQC: SUVmax</td></tr><tr><td>Factor</td><td>Low</td><td>High</td><td>Pvalue</td><td>Low</td><td>High</td><td>Pvalue</td></tr><tr><td>Pleural invasion</td><td></td><td></td><td>0.027</td><td></td><td></td><td>0.064</td></tr><tr><td>No</td><td>19</td><td... | <table><tr><td></td><td colspan="3">ADC: SUVmax</td><td colspan="3">SQC: SUVmax</td></tr><tr><td>Factor</td><td>Low</td><td>High</td><td>Pvalue</td><td>Low</td><td>High</td><td>Pvalue</td></tr><tr><td>Ki-67 expression</td><td></td><td></td><td>0.011</td><td></td><td></td><td>0.087</td></tr><tr><td>Negative</td><td>15</... |
527a53e2defdf81eea993b87a8930c3b658e7fb8b5572d760f1fe9c6cb82fba0.png | complex | <table><tr><td>Accession</td><td>Hydroxycinnamic Acids</td><td>ORAC</td><td>DPPH</td><td>TRC</td><td>NO Inhibition</td></tr><tr><td colspan="6"><i>S. muricatum</i></td></tr><tr><td>37-A</td><td>5</td><td>2</td><td>4</td><td>2</td><td>1</td></tr><tr><td>El Camino</td><td>3</td><td>4</td><td>5</td><td>4</td><td>5</td></t... | <table><tr><td>Accession</td><td>Hydroxycinnamic Acids</td><td>ORAC</td><td>DPPH</td><td>TRC</td><td>NO Inhibition</td></tr><tr><td colspan="6">S. muricatum</td></tr><tr><td>37-A</td><td>5</td><td>2</td><td>4</td><td>2</td><td>1</td></tr><tr><td>El Camino</td><td>3</td><td>4</td><td>5</td><td>4</td><td>5</td></tr></tab... | <table><tr><td>Accession</td><td>Hydroxycinnamic Acids</td><td>ORAC</td><td>DPPH</td><td>TRC</td><td>NO Inhibition</td></tr><tr><td>Puzol</td><td>2</td><td>3</td><td>2</td><td>5</td><td>2</td></tr><tr><td>Valencia</td><td>1</td><td>5</td><td>3</td><td>3</td><td>4</td></tr><tr><td colspan="6">S. caripense</td></tr><tr><... |
495e09e702afbe3e0dfb4b116e1bd2b9f4e03b612524abe3bb853d84a9867030.png | complex | <table><tr><td rowspan="3">Region</td><td colspan="2">Diseased animals</td><td colspan="2">Apparently healthy animals</td><td colspan="2">Total</td></tr><tr><td>Number of isolates as detected from 16SrRNA</td><td>Positive for <i>SeM</i> gene</td><td>Number of isolates as detected from 16SrRNA</td><td>Positive for <i>Se... | <table><tr><td rowspan="3">Region</td></tr><tr></tr><tr></tr><tr><td>R.S. Pura</td></tr><tr><td>Katra</td></tr><tr><td>Total</td></tr></table> | <table><tr><td colspan="2">Diseased animals</td><td colspan="2">Apparently healthy animals</td><td colspan="2">Total</td></tr><tr><td>Number of isolates as detected from 16SrRNA</td><td>Positive for SeM gene</td><td>Number of isolates as detected from 16SrRNA</td><td>Positive for SeM gene</td><td>Number of isolates as ... |
bc94cfb3fd4f232d6183cda1f276ce61d848770e61e643d28abd232445df8c8f.png | complex | <table><tr><td></td><td>Brain region</td><td>Hemisphere</td><td>NVtxs</td><td>Size (mm<sup>2</sup>)</td><td>X</td><td>Y</td><td>Z</td><td>Max</td><td>CWP</td></tr><tr><td colspan="10"><i>Group comparisons</i></td></tr><tr><td>HC > CD</td><td>Superior temporal gyrus</td><td>R</td><td>338</td><td>154.4</td><td>64</td>... | <table><tr><td></td><td>Brain region</td><td>Hemisphere</td><td>NVtxs</td><td>Size (mm2)</td><td>X</td><td>Y</td></tr><tr><td colspan="7">Group comparisons</td></tr><tr><td>HC > CD</td><td>Superior temporal gyrus</td><td>R</td><td>338</td><td>154.4</td><td>64</td><td>−37</td></tr><tr><td>CD > HC</td><td>None significan... | <table><tr><td>Z</td><td>Max</td><td>CWP</td></tr><tr><td colspan="3">Group comparisons</td></tr><tr><td>13</td><td>3.5</td><td>0.001</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan="3">Correlation with CU traits in the CD group</td></tr><tr><td>−2</td><td>4.3</td><td>0.... |
79951c92d93fe30330109e0f83dd43ca9294fccade439d1ea6acaa1406a77a35.png | simple | <table><tr><td>NHI Code</td><td>Treatment</td><td>(n = 13,261)</td><td>%</td></tr><tr><td>45010C</td><td>Supportive individual psychotherapy</td><td>2117</td><td>16.0</td></tr><tr><td>45087C</td><td>Re-educative individual psychotherapy-adult</td><td>1578</td><td>11.9</td></tr><tr><td>45088C</td><td>Re-educative indivi... | <table><tr><td>NHI Code</td></tr><tr><td>45010C</td></tr><tr><td>45087C</td></tr><tr><td>45088C</td></tr><tr><td>45100C</td></tr><tr><td>45013C</td></tr><tr><td>45016C</td></tr><tr><td>45094C</td></tr><tr><td>45022C</td></tr><tr><td>45043C</td></tr><tr><td>45089C</td></tr><tr><td>45095C</td></tr><tr><td>45090C</td></tr... | <table><tr><td>Treatment</td><td>(n = 13,261)</td><td>%</td></tr><tr><td>Supportive individual psychotherapy</td><td>2117</td><td>16.0</td></tr><tr><td>Re-educative individual psychotherapy-adult</td><td>1578</td><td>11.9</td></tr><tr><td>Re-educative individual psychotherapy: 6–15 years old</td><td>127</td><td>1.0</td... |
d5996ba9872141421ca0a9d147d900e81884028e0e315488486600f4c6de7e6b.png | simple | <table><tr><td></td><td>All patients</td><td>L5/S1 herniations with high iliac crest</td><td>Herniations with scoliosis</td><td>Herniation with calcification</td></tr><tr><td>No. of patients in category</td><td>209</td><td>29</td><td>25</td><td>31</td></tr><tr><td>Excellent or good <i>n</i> (%)</td><td>200 (95.7)</td><... | <table><tr><td></td><td>All patients</td><td>L5/S1 herniations with high iliac crest</td><td>Herniations with scoliosis</td><td>Herniation with calcification</td></tr><tr><td>No. of patients in category</td><td>209</td><td>29</td><td>25</td><td>31</td></tr></table> | <table><tr><td></td><td>All patients</td><td>L5/S1 herniations with high iliac crest</td><td>Herniations with scoliosis</td><td>Herniation with calcification</td></tr><tr><td>Excellent or good n (%)</td><td>200 (95.7)</td><td>29 (100)</td><td>25 (100)</td><td>30 (96.8)</td></tr><tr><td>Fair n (%)</td><td>6 (2.9)</td><t... |
f7cf35b15f05e8043bc45a01c19cb44e979746c17e31d2ba029d27cba0dcfb7f.png | simple | <table><tr><td></td><td>RL</td><td>AP</td><td>SI</td><td>Net</td></tr><tr><td>Range</td><td>0-0.85</td><td>0-1.83</td><td>0-1.96</td><td>0.10-2.01</td></tr><tr><td>Average (Right shoulder)</td><td>0.22</td><td>0.36</td><td>0.35</td><td>0.55</td></tr><tr><td>Average (Left shoulder)</td><td>0.26</td><td>0.48</td><td>0.27... | <table><tr><td></td></tr><tr><td>Range</td></tr><tr><td>Average (Right shoulder)</td></tr><tr><td>Average (Left shoulder)</td></tr><tr><td>Average net</td></tr></table> | <table><tr><td>RL</td><td>AP</td><td>SI</td><td>Net</td></tr><tr><td>0-0.85</td><td>0-1.83</td><td>0-1.96</td><td>0.10-2.01</td></tr><tr><td>0.22</td><td>0.36</td><td>0.35</td><td>0.55</td></tr><tr><td>0.26</td><td>0.48</td><td>0.27</td><td>0.60</td></tr><tr><td></td><td></td><td></td><td>0.58</td></tr></table> |
f958b46f8a326e511cda2f099cf8f878492efd28e18a97d71c44e514f8b57a9e.png | simple | <table><tr><td>F508del</td><td>Sex</td><td>Male</td><td>Female</td><td>Chi-square</td><td>p-value</td></tr><tr><td>-/-</td><td>G/G</td><td>8 (53.3%)</td><td>7 (46.7%)</td><td>0.257</td><td>0.613</td></tr><tr><td> </td><td>G/T and T/T</td><td>15 (45.5%)</td><td>18 (54.5%)</td><td> </td><td> </td></tr><tr><td>F508del/-</... | <table><tr><td>F508del</td><td>Sex</td><td>Male</td><td>Female</td><td>Chi-square</td><td>p-value</td></tr><tr><td>-/-</td><td>G/G</td><td>8 (53.3%)</td><td>7 (46.7%)</td><td>0.257</td><td>0.613</td></tr><tr><td></td><td>G/T and T/T</td><td>15 (45.5%)</td><td>18 (54.5%)</td><td></td><td></td></tr><tr><td>F508del/-</td>... | <table><tr><td></td><td>G/T and T/T</td><td>30 (90.9%)</td><td>3 (9.1%)</td><td></td><td></td></tr><tr><td>F508del/-</td><td>G/G</td><td>22 (81.5%)</td><td>5 (18.5%)</td><td>0.067</td><td>0.795</td></tr><tr><td></td><td>G/T and T/T</td><td>26 (78.8%)</td><td>7 (21.2%)</td><td></td><td></td></tr><tr><td>F508del/F508del<... |
442b92b67e2c74cfa7fe57b142ba87a4330d6ad8c08a5db6e2e5bb4dda9fdc06.png | simple | <table><tr><td>Study reference</td><td>Study design</td><td>Reported inclusion/exclusion criteria</td><td>Reported double blind</td><td>Reported clinically-labeled products</td><td>Reported sample power estimation</td><td>Reported adverse events</td><td>Reported study completion ratio</td><td>Overall quality factor sco... | <table><tr><td>Study reference</td><td>Study design</td><td>Reported inclusion/exclusion criteria</td><td>Reported double blind</td><td>Reported clinically-labeled products</td><td>Reported sample power estimation</td><td>Reported adverse events</td><td>Reported study completion ratio</td><td>Overall quality factor sco... | <table><tr><td>Study reference</td><td>Study design</td><td>Reported inclusion/exclusion criteria</td><td>Reported double blind</td><td>Reported clinically-labeled products</td><td>Reported sample power estimation</td><td>Reported adverse events</td><td>Reported study completion ratio</td><td>Overall quality factor sco... |
06df98beaa79f3380b3c6ea699d544542d7765cd2b656287f141207ccefa71f4.png | complex | <table><tr><td rowspan="2"></td><td>With tumor thrombus</td><td rowspan="2"><i>P</i></td><td>Without tumor thrombus</td><td rowspan="2"><i>P</i></td></tr><tr><td>OR(%95 CI)</td><td>OR (%95 CI)</td></tr><tr><td>AFP, ng/mL (> 20 vs. ≤ 20)</td><td>1.1 (0.9, 1.3)</td><td>0.479</td><td>1.1 (0.7, 1.7)</td><td>0.746<... | <table><tr><td rowspan="2"></td><td>With tumor thrombus</td><td rowspan="2">P</td><td>Without tumor thrombus</td><td rowspan="2">P</td></tr><tr><td>OR(%95 CI)</td><td>OR (%95 CI)</td></tr><tr><td>AFP, ng/mL (> 20 vs. ≤ 20)</td><td>1.1 (0.9, 1.3)</td><td>0.479</td><td>1.1 (0.7, 1.7)</td><td>0.746</td></tr><tr><td>Tumor ... | <table><tr><td rowspan="2"></td><td>With tumor thrombus</td><td rowspan="2">P</td><td>Without tumor thrombus</td><td rowspan="2">P</td></tr><tr><td>OR(%95 CI)</td><td>OR (%95 CI)</td></tr><tr><td>er (> 3 vs. ≤ 3)</td><td>.3)</td><td>992</td><td></td><td>.328</td></tr><tr><td>Tumor location (more than one vs. one lobe)<... |
9c8962529187e349e7994f2b87f86b0b41eb8255616ab1cd14eb7ed9c8cbfd0a.png | simple | <table><tr><td>No</td><td>A</td><td>B</td><td>C</td><td>D</td><td>extract weight(%)y1</td><td>TTC(%)y2</td><td>score z</td></tr><tr><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>56.76</td><td>22.54</td><td>73.79</td></tr><tr><td>2</td><td>1</td><td>2</td><td>2</td><td>2</td><td>69.10</td><td>24.97</td><td>85.14... | <table><tr><td>No</td><td>A</td><td>B</td><td>C</td><td>D</td><td>extract weight(%)y1</td><td>TTC(%)y2</td><td>score z</td></tr><tr><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>56.76</td><td>22.54</td><td>73.79</td></tr><tr><td>2</td><td>1</td><td>2</td><td>2</td><td>2</td><td>69.10</td><td>24.97</td><td>85.14... | <table><tr><td>3</td><td>1</td><td>3</td><td>3</td><td>3</td><td>73.18</td><td>30.92</td><td>98.65</td></tr><tr><td>4</td><td>2</td><td>1</td><td>2</td><td>3</td><td>72.14</td><td>31.63</td><td>99.44</td></tr><tr><td>5</td><td>2</td><td>2</td><td>3</td><td>1</td><td>34.94</td><td>26.04</td><td>68.46</td></tr><tr><td>6<... |
7156f2cbac62cc874d6f614518f24f61d47efb9f21ced9ef6b4e2cf2ba032c8a.png | simple | <table><tr><td> </td><td><i>WT</i></td><td><i>+/-</i></td><td><i>-/-</i></td></tr><tr><td>Early-stage seizure</td><td>0</td><td>+</td><td>++</td></tr><tr><td>Myoclonic jerks</td><td>0</td><td>+*</td><td>0</td></tr><tr><td>Clonic seizure</td><td>0</td><td>−*</td><td>−−</td></tr><tr><td>Repetitive jumpi... | <table><tr><td></td><td>WT</td><td>+/-</td><td>-/-</td></tr><tr><td>Early-stage seizure</td><td>0</td><td>+</td><td>++</td></tr><tr><td>Myoclonic jerks</td><td>0</td><td>+*</td><td>0</td></tr><tr><td>Clonic seizure</td><td>0</td><td>−*</td><td>−−</td></tr><tr><td>Repetitive jumping</td><td>0</td><td>(+)</td><td>++</td>... | <table><tr><td>erence</td><td>0</td><td>+)</td><td>+</td></tr><tr><td>Ultrasonic vocalization</td><td>0</td><td>(−)*</td><td>−−</td></tr><tr><td>Nest building</td><td>0</td><td>−</td><td>−−</td></tr><tr><td>Acoustic startle response</td><td>0</td><td>−</td><td>−−</td></tr><tr><td>Prepulse inhibition</td><td>0</td><td>(... |
4722c45252e375db01143e74ac5724bb201ab176c933675e694358bcd6765b4e.png | simple | <table><tr><td>Up-regulated miRNAs</td><td>Fold-change</td><td><i>P</i></td></tr><tr><td>miR-7</td><td>10.91</td><td>0.005</td></tr><tr><td>miR-196b</td><td>7.67</td><td>0.030</td></tr><tr><td>miR-424</td><td>6.75</td><td>0.008</td></tr><tr><td>miR-18b</td><td>6.67</td><td>0.002</td></tr><tr><td>miR-223</td><td>6.31</t... | <table><tr><td>Up-regulated miRNAs</td><td>Fold-change</td><td>P</td></tr><tr><td>miR-7</td><td>10.91</td><td>0.005</td></tr><tr><td>miR</td><td>7</td><td>0.0</td></tr></table> | <table><tr><td>-196b</td><td>.67</td><td>30</td></tr><tr><td>miR-424</td><td>6.75</td><td>0.008</td></tr><tr><td>miR-18b</td><td>6.67</td><td>0.002</td></tr><tr><td>miR-223</td><td>6.31</td><td>0.003</td></tr><tr><td>miR-130b</td><td>5.18</td><td>0.005</td></tr></table> |
f49227b2874551f92bac8eaed2ceebf875f16ab33ecadffa9b84e9ba23b77a8e.png | complex | <table><tr><td>Statement</td><td>Depression Vignette</td><td>Depression/Suicidal Vignette</td><td>Early Schizophrenia Vignette</td><td>Chronic Schizophrenia Vignette</td></tr><tr><td colspan="5">Person could snap out of the problem</td></tr><tr><td>Australian</td><td>24.7 (21.7%–27.9%)</td><td>22.7 (19.9%–2... | <table><tr><td>Statement</td><td>Depression Vignette</td><td>Depression/Suicidal Vignette</td><td>Early Schizophrenia Vignette</td><td>Chronic Schizophrenia Vignette</td></tr><tr><td colspan="5">Person could snap out of the problem</td></tr><tr><td>Australian</td><td>24.7 (21.7%–27.9%)</td><td>22.7 (19.9%–25.7%)</td><t... | <table><tr><td>Japanese</td><td>18.6 * c,d (15.2%–22.0%)</td><td>20.0 * c,d (16.5%–23.5%)</td><td>31.0 * a,b,d (26.9%–35.1%)</td><td>45.6 * a,b,c (41.2%–50.0%)</td></tr><tr><td colspan="5">If I had this problem I wouldn't tell anyone</td></tr><tr><td>Australian</td><td>17.0 c,d (14.5%–19.9%)</td><td>21.5 d (18.8%–24.3%... |
7b42396457df0300486da1691278c17cd6040b06b61540e1ba3dbf6df8fc78d9.png | complex | <table><tr><td></td><td colspan="2">OR (95% CI)</td></tr><tr><td>Pregnancy outcome (<i>n</i>)</td><td>Unadjusted</td><td>Adjusteda</td></tr><tr><td colspan="3">Term [≥ 37 weeks (923)]</td></tr><tr><td>All preterm [< 37 weeks (101)]</td><td>1.1 (0.6–2.2)</td><td>1.55 (0.7–2.9)</td></tr><tr><td>Moder... | <table><tr><td></td></tr><tr><td>Pregnancy outcome (n)</td></tr><tr><td>Term [≥ 37 weeks (923)]</td></tr><tr><td>All preterm [< 37 weeks (101)]</td></tr><tr><td>Moderately preterm [35–36 weeks (57)]</td></tr><tr><td>Very preterm [< 35 weeks (44)]</td></tr></table> | <table><tr><td colspan="2">OR (95% CI)</td></tr><tr><td>Unadjusted</td><td>Adjusteda</td></tr><tr><td colspan="2">Term [≥ 37 weeks (923)]</td></tr><tr><td>1.1 (0.6–2.2)</td><td>1.55 (0.7–2.9)</td></tr><tr><td>0.3 (0.1–1.4)</td><td>0.4 (0.1–1.9)</td></tr><tr><td>2.4 (1.1–5.1)</td><td>3.0 (1.3–6.7)</td></tr></table> |
776dd136dac17669ad393c92072448a01f9d6bf4942a03b643093d4ba21e731f.png | simple | <table><tr><td>Targeted agent</td><td>Chemotherapy</td><td>N</td><td>RR</td><td>PFS (months)</td><td>OS (months)</td><td>Reference</td></tr><tr><td>Cetuximab</td><td>Irinotecan and FU</td><td>49</td><td>42%</td><td>8.6</td><td>16.6</td><td>Kanzler et al. [11]</td></tr><tr><td>Bevacizumab</td><td>Docetaxel, FU and cispl... | <table><tr><td>Targeted agent</td><td>Chemotherapy</td><td>N</td><td>RR</td><td>PFS (months)</td><td>OS (months)</td><td>Reference</td></tr><tr><td>Cetuximab</td><td>Irinotecan and FU</td><td>49</td><td>42%</td><td>8.6</td><td>16.6</td><td>Kanzler et al. [11]</td></tr></table> | <table><tr><td>Targeted agent</td><td>Chemotherapy</td><td>N</td><td>RR</td><td>PFS (months)</td><td>OS (months)</td><td>Reference</td></tr><tr><td>Bevacizumab</td><td>Docetaxel, FU and cisplatin</td><td>44</td><td>67%</td><td>12</td><td>16.2</td><td>Kelsen et al. [12]</td></tr><tr><td>Cetuximab</td><td>Irinotecan and ... |
699de5b5f7816bc5c7a164cfc57c66d4e5fe8327e7e69af6d7ee32b898775d82.png | simple | <table><tr><td>ID</td><td>Protein change</td><td><sup>a</sup>Nucleotide change</td><td>Mutation type</td><td><sup>d</sup>PolyPhen-2</td><td><sup>e</sup>SIFT</td><td>Predicted function</td><td>Mutant ratio</td></tr><tr><td>777T</td><td>Y249X</td><td>747T>A</td><td></td><td>nonsense</td><td></td><td>Loss of function</... | <table><tr><td>ID</td><td>Protein change</td><td>aNucleotide change</td><td>Mutation type</td><td>dPolyPhen-2</td><td>eSIFT</td><td>Predicted function</td><td>Mutant ratio</td></tr><tr><td>777T</td><td>Y249X</td><td>747T>A</td><td></td><td>nonsense</td><td></td><td>Loss of function</td><td>0.91</td></tr><tr><td>869T</t... | <table><tr><td>1278T</td><td>F1250del</td><td>3747_3749del</td><td>in-frame del</td><td>Uncertain</td><td>0.14</td></tr><tr><td>bACCMESO1</td><td>V132EfsX3</td><td>395_399del5</td><td>frameshift</td><td>Loss of function</td><td></td></tr><tr><td>cNYU695</td><td>K674SfsX73</td><td>2020delA</td><td>frameshift</td><td>Los... |
db9027bf58d278ad8dd431bc1c655b901be68339dde06d822d6e0cdc0097581c.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">Johnsen Score</td><td rowspan="2">Parameters</td><td rowspan="2">Area Under the Curve</td><td rowspan="2">Std. Error</td><td rowspan="2">Asymptotic Sig.</td><td colspan="2">Asymptomic 95% Confidence Interval</td></tr><tr><td>Lower Bound</td><td>Upper Bound</td></tr><tr><t... | <table><tr><td rowspan="2"></td><td rowspan="2">Johnsen Sco</td><td rowspan="2"></td><td rowspan="2">Ar</td><td rowspan="2">Std</td><td rowspan="2">Asympt</td><td colspan="2">Asymptomic 95% Confidence Interval</td></tr><tr><td>Low</td><td>Upper Bound</td></tr></table> | <table><tr><td></td><td>re</td><td>Parameters</td><td>ea Under the Curve</td><td>. Error</td><td>otic Sig.</td><td>er Bound</td><td></td></tr><tr><td rowspan="7">Left Testis</td><td rowspan="2">≥8</td><td>Testis Volume</td><td>0.796</td><td>0.034</td><td>0.000</td><td>0.729</td><td>0.863</td></tr><tr><td>TT</td><td>0.5... |
31b57836600699f39bcabda53f8dbd4308c4a580c2f1443f84e6c02a8303a096.png | simple | <table><tr><td>No.</td><td>Age</td><td>Gender</td><td>BSA (m<sup>2</sup>)</td><td>MSKCC risk</td><td>Metastatic sites</td><td>Prior therapy</td></tr><tr><td>1</td><td>70</td><td>Female</td><td>1.298</td><td>Intermediate</td><td>Lung, Lymph nodes</td><td>None</td></tr><tr><td>2</td><td>58</td><td>Female</td><td>1.446</t... | <table><tr><td>No.</td><td>Age</td><td>Gender</td><td>BSA (m2)</td><td>MSKCC risk</td></tr><tr><td>1</td><td>70</td><td>Female</td><td>1.298</td><td>Intermediate</td></tr><tr><td>2</td><td>58</td><td>Female</td><td>1.446</td><td>Favorable</td></tr><tr><td>3</td><td>56</td><td>Male</td><td>1.929</td><td>Intermediate</td... | <table><tr><td>Metastatic sites</td><td>Prior therapy</td></tr><tr><td>Lung, Lymph nodes</td><td>None</td></tr><tr><td>Abdominal wall, Lung, liver</td><td>None</td></tr><tr><td>Lung</td><td>Interferon</td></tr><tr><td>Pancreas, Contralateral kidney</td><td>None</td></tr><tr><td>Pleura</td><td>None</td></tr><tr><td>Lung... |
0e0d453764ad5a7ee457efb2edcf6364da79d706fc79282318356deaa44dcd5b.png | complex | <table><tr><td>Dependent variable: 2009 performance score</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td></tr><tr><td>Private</td><td>−6.212</td><td>−7.030</td><td>−7.026</td><td>−5.548</td><td>−5.311</td... | <table><tr><td>Dependent variable: 2009 performance score</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td></tr><tr><td>Private</td><td>−6.212</td><td>−7.030</td><td>−7.026</td><td>−5.548</td><td>−5.311</td></tr><tr><td></td><td>(3.651)*</td>... | <table><tr><td>Dependent variable: 2009 performance score</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td></tr><tr><td>Number of staff members</td><td>0.206</td><td>0.147</td><td>0.120</td><td>0.362</td><td>0.323</td></tr><tr><td></td><td>(0... |
1a74357a872ceb0dcdfab8ce96e23c24cb8ce63773b6154e048c1d97e7ff0664.png | simple | <table><tr><td>Sequence</td><td>Faster adaptation for the lens of period 1 (immediate or few hours)</td><td>No difference</td><td>Faster adaptation for the lens of period 2 (immediate or few hours)</td><td>TOTAL</td></tr><tr><td></td><td>N</td><td>N</td><td>N</td><td>N</td></tr><tr><td>New-generation lens then older-ge... | <table><tr><td>Sequence</td><td>Faster adaptation for the lens of period 1 (immediate or few hours)</td><td>No difference</td><td>Faster adaptation for the lens of period 2 (immediate or few hours)</td><td>TOTAL</td></tr><tr><td></td><td>N</td><td>N</td><td>N</td><td>N</td></tr><tr><td>New-generation lens then older-ge... | <table><tr><td>Older-generation lens then new-generation lens</td><td>5</td><td>39</td><td>19</td><td>63</td></tr><tr><td>TOTAL</td><td>19</td><td>74</td><td>31</td><td>124</td></tr></table> |
6adcf219b36f470e2842b66e8dec55166427890746811fc683c6f96202e744c0.png | simple | <table><tr><td>Outcomes</td><td>Lifestyle intervention group n = 27<sup>a</sup></td><td>Close follow-up group n = 27</td><td>p value<sup>b</sup></td></tr><tr><td>Total weight gain (kg)</td><td>11.4 ± 6.0</td><td>13.9 ± 5.1</td><td>NS</td></tr><tr><td>Weight at the end of pregnancy ( kg)</td><td>88.6 ± 14... | <table><tr><td>Outcomes</td><td>Lifestyle intervention group n = 27a</td><td>Close follow-up group n = 27</td><td>p valueb</td></tr><tr><td>Total weight gain (kg)</td><td>11.4 ± 6.0</td><td>13.9 ± 5.1</td><td>NS</td></tr><tr><td>Weight at the end of pregnancy ( kg)</td><td>88.6 ± 14.4</td><td>84.1 ± 11.3</td><td>NS</td... | <table><tr><td>Outcomes</td><td>Lifestyle intervention group n = 27a</td><td>Close follow-up group n = 27</td><td>p valueb</td></tr><tr><td>ur glucose (mmol/l)</td><td>4</td><td></td><td>NS</td></tr><tr><td>Area under the curve (mmol/l/2 h)</td><td>12.3 ± 2.4</td><td>12.1 ± 2.2</td><td>NS</td></tr><tr><td>Gestational d... |
f1417f141fdf08cd0db6ada419c8018ebd70d33db5ace503f4a737fa79788ee7.png | complex | <table><tr><td></td><td>Obese non-diabetic(<i>n</i> = 138)</td><td>Obese diabetic(<i>n</i> = 92)</td><td><i>p</i></td></tr><tr><td colspan="4">Physical and clinical characteristics</td></tr><tr><td>Age (years)</td><td>45.76 ± 9.91</td><td>48.28 ± 8.17</td><td>0.16</td></tr><tr><td>Gender (M/F)</td><td>71/67</... | <table><tr><td></td><td>Obese non-diabetic(n = 138)</td><td>Obese diabetic(n = 92)</td><td>p</td></tr><tr><td colspan="4">Physical and clinical characteristics</td></tr><tr><td>Age (years)</td><td>45.76 ± 9.91</td><td>48.28 ± 8.17</td><td>0.16</td></tr><tr><td>Gender (M/F)</td><td>71/67</td><td>49/43</td><td>0.44</td><... | <table><tr><td>IL-1b (pg/L)</td><td>8.29 ± 3.28</td><td>7.82 ± 1.94</td><td>0.96</td></tr><tr><td>IL-6 (pg/mL)</td><td>17.30 ± 6.24</td><td>17.16 ± 4.87</td><td>0.71</td></tr><tr><td>IL-10 (pg/mL)</td><td>28.47 ± 20.05</td><td>33.02 ± 27.87</td><td>0.50</td></tr><tr><td>IP-10 (pg/mL)</td><td>571 ± 418</td><td>689 ± 617... |
75f5e8d72ea49b182ae49c18396ce62655bdb9d12549903a150b7e3628797d23.png | complex | <table><tr><td>Working countries</td><td colspan="2">Health problems suffered during last 12 month</td><td>Total</td></tr><tr><td></td><td>Yes (%)</td><td>No (%)</td><td></td></tr><tr><td>Qatar</td><td>120 (58.5)</td><td>85 (41.5)</td><td>205</td></tr><tr><td>Saudi Arabia</td><td>74 (54.0)</td><td>63 (46.0)</td><td>137... | <table><tr><td>Working countries</td><td colspan="2">Health problems suffered during last 12 month</td><td>Total</td></tr><tr><td></td><td>Yes (%)</td><td>No (%)</td><td></td></tr></table> | <table><tr><td>Qatar</td><td>120 (58.5)</td><td>85 (41.5)</td><td>205</td></tr><tr><td>Saudi Arabia</td><td>74 (54.0)</td><td>63 (46.0)</td><td>137</td></tr><tr><td>United Arab Emirates</td><td>37 (56.1)</td><td>29 (43.9)</td><td>66</td></tr><tr><td>Total</td><td>231 (56.6)</td><td>177 (43.4)</td><td>408</td></tr><tr><... |
94be6a95c5841f0550402775c72a7050e59197c5483342696440c783a2b993d3.png | complex | <table><tr><td></td><td colspan="2">Univariate logistic regression</td><td colspan="2">Multivariable logistic regression</td></tr><tr><td>Variable</td><td>OR (95% CI)</td><td>p-value</td><td>OR (95% CI)</td><td>p-value</td></tr><tr><td>Year</td><td></td><td></td><td></td><td></td></tr><tr><td><i>For every 1-year increa... | <table><tr><td></td><td colspan="2">Univariate logistic regression</td><td colspan="2">Multivariable logistic regression</td></tr><tr><td>Variable</td><td>OR (95% CI)</td><td>p-value</td><td>OR (95% CI)</td><td>p-value</td></tr><tr><td>Year</td><td></td><td></td><td></td><td></td></tr><tr><td>For every 1-year increase<... | <table><tr><td>Breast</td><td>1.38 (0.82 – 2.33)</td><td>0.22</td><td>1.34 (0.70 – 2.56)</td><td>0.38</td></tr><tr><td>Liver/colorectal/stomach</td><td>0.66 (0.34 – 1.27)</td><td>0.21</td><td>0.52 (0.24 – 1.10)</td><td>0.09</td></tr><tr><td>Funding</td><td></td><td></td><td></td><td></td></tr><tr><td>Not for profit/Mix... |
077c32b755ee7c6a0af9540c6cd4c5a237d935fa3b36e03696a0e63ad37e6705.png | simple | <table><tr><td>Studies</td><td><i>n</i></td><td>Procedures</td><td>Mean age ± SD (yr) (min–max)</td><td>Described complication</td><td>% found in each study</td><td>Equivalent % in our cohort</td></tr><tr><td>Sury et al., 1999 [3]</td><td>1155</td><td>MRI</td><td>N/A</td><td>Failure</td><td>5</td><td>2.3</td... | <table><tr><td>Studies</td><td>n</td><td>Procedures</td><td>Mean age ± SD (yr) (min–max)</td><td>Described complication</td><td>% found in each study</td><td>Equivalent % in our cohort</td></tr><tr><td>Sury et al., 1999 [3]</td><td>1155</td><td>MRI</td><td>N/A</td><td>Failure</td><td>5</td><td>2.3</td></tr><tr><td>Beeb... | <table><tr><td>Studies</td><td>n</td><td>Procedures</td><td>Mean age ± SD (yr) (min–max)</td><td>Described complication</td><td>% found in each study</td><td>Equivalent % in our cohort</td></tr><tr><td>Cravero et al., 2009 [10]</td><td>49836</td><td>Imaging (60%) Oncology (14%) GI (11%)</td><td>0–6 mo : 2% 6–12 mo : 6%... |
34ecc799e700053f7eb9f769cd6ad845b2df36e2cbcb4309a7a71f35c78c6969.png | complex | <table><tr><td>Method</td><td>Temporal resolution</td><td>Measure</td><td>Span of interest</td><td colspan="2">General functionality</td><td>Hypothesized emotion-related functionality</td></tr><tr><td>ERP</td><td>Higher (as low as 1 ms)</td><td>Amplitude fluctuations evoked by stimulus</td><td>Short (∼1 s)</td><t... | <table><tr><td>Method</td><td>Temporal resolution</td><td>Measure</td><td>Span of interest</td><td colspan="2">General functionality</td><td>Hypothesized emotion-related functionality</td></tr></table> | <table><tr><td>ERP</td><td>Higher (as low as 1 ms)</td><td>Amplitude fluctuations evoked by stimulus</td><td>Short (∼1 s)</td><td>Early (e.g., P1, N1, N170)</td><td>Perceptual feature extraction</td><td>Early selective attention to affective stimuli</td></tr><tr><td></td><td></td><td></td><td></td><td>Middle (e.g., P2,... |
c3a2341ab7b7e2eeb89cb55bee65aa60a76bc86b043390bc99fc754ca0f1ad73.png | simple | <table><tr><td></td><td>Odds ratio (95% confidence interval)</td><td>P value</td></tr><tr><td>Age</td><td>1.04 (1.01-1.07)</td><td>0.0022</td></tr><tr><td>BMI</td><td>0.98 (0.93-1.03)</td><td>0.4578</td></tr><tr><td>Female sex</td><td>0.79 (0.47-1.34)</td><td>0.3952</td></tr><tr><td>DR</td><td>1.71 (1.03-2.85)</td><td>... | <table><tr><td></td><td>Odds ratio (95% confidence interval)</td><td>P value</td></tr><tr><td>Age</td><td>1.04 (1.01-1.07)</td><td>0.0022</td></tr><tr><td>BMI</td><td>0.98 (0.93-1.03)</td><td>0.4578</td></tr><tr><td>Female sex</td><td>0.79 (0.47-1.34)</td><td>0.3952</td></tr><tr><td>DR</td><td>1.71 (1.03-2.85)</td><td>... | <table><tr><td></td><td>Odds ratio (95% confidence interval)</td><td>P value</td></tr><tr><td>UAE</td><td>0.99 (0.99-1.00)</td><td>0.6397</td></tr></table> |
4ce9deef60240ee5914d52e6a5479745b486753c21666ce3f346437e04e69e2b.png | simple | <table><tr><td></td><td>Cavus</td><td>Neutral</td><td>Planus</td><td>P-value</td></tr><tr><td>N (female)</td><td>53 (5)</td><td>184 (34)</td><td>711 (133)</td><td></td></tr><tr><td>AHF (mm/kN)</td><td>13.2 ± 7.4</td><td>14.8 ± 7.4</td><td>16.6 ± 7.4</td><td>0.0001 <sup>a,c</sup></td></tr><tr><td>ΔFo... | <table><tr><td></td><td>Cavus</td><td>Neutral</td><td>Planus</td><td>P-value</td></tr></table> | <table><tr><td>N (female)</td><td>53 (5)</td><td>184 (34)</td><td>711 (133)</td><td></td></tr><tr><td>AHF (mm/kN)</td><td>13.2 ± 7.4</td><td>14.8 ± 7.4</td><td>16.6 ± 7.4</td><td>0.0001 a,c</td></tr><tr><td>ΔFoot Length (mm)</td><td>4.8 ± 2.6</td><td>4.3 ± 2.2</td><td>3.6 ± 2.1</td><td><.0001 a,c</td></tr></table> |
59e81cbef37f8ac237f95278ac56a194e3f56361fe6261540d281df1569731db.png | complex | <table><tr><td rowspan="2">Climate model</td><td colspan="3">Seasonal mean temperature (<sup>o</sup>C)</td><td colspan="3">Seasonal cumulated rainfall (mm)</td></tr><tr><td>2030</td><td>2050</td><td>2070</td><td>2030</td><td>2050</td><td>2070</td></tr><tr><td><i>ACCESS1-0</i></td><td>14.3 ± 1.7</td><td>15.1 ±... | <table><tr><td rowspan="2">Climate model</td><td colspan="3">Seasonal mean temperature (oC)</td><td colspan="3">Seasonal cumulated rainfall (mm)</td></tr><tr><td>2030</td><td>2050</td><td>2070</td><td>2030</td><td>2050</td><td>2070</td></tr><tr><td>ACCESS1-0</td><td>14.3 ± 1.7</td><td>15.1 ± 1.8</td><td>16.1 ± 1.9</td>... | <table><tr><td rowspan="2">Climate model</td><td colspan="3">Seasonal mean temperature (oC)</td><td colspan="3">Seasonal cumulated rainfall (mm)</td></tr><tr><td>2030</td><td>2050</td><td>2070</td><td>2030</td><td>2050</td><td>2070</td></tr><tr><td>GFDL-ESM2M</td><td>14.3 ± 1.9</td><td>14.8 ± 2.0</td><td>15.7 ± 2.1</td... |
efb3836579f5a42ae21da830136f2589cdc91385e84e03014929167311a79fba.png | complex | <table><tr><td></td><td colspan="2">Changes in WHtR*<sup>1¶</sup></td><td colspan="2">Changes in weight*<sup>2</sup> [kg]</td><td colspan="2">Changes in BMI percentiles*<sup>3</sup></td></tr><tr><td></td><td>(<i>n</i> = 1252)</td><td></td><td>(<i>n</i> = 1251)</td><td></td><td>(<i>n</i> = 1250)</td><td></td></tr><... | <table><tr><td></td><td colspan="2">Changes in WHtR*1¶</td><td colspan="2">Changes in weight*2 [kg]</td><td colspan="2">Changes in BMI percentiles*3</td></tr><tr><td></td><td>(n = 1252)</td><td></td><td>(n = 1251)</td><td></td><td>(n = 1250)</td><td></td></tr><tr><td></td><td>B (SE)</td><td>p-value</td><td>B (SE)</td><... | <table><tr><td></td><td colspan="2">Changes in WHtR*1¶</td><td colspan="2">Changes in weight*2 [kg]</td><td colspan="2">Changes in BMI percentiles*3</td></tr><tr><td></td><td>(n = 1252)</td><td></td><td>(n = 1251)</td><td></td><td>(n = 1250)</td><td></td></tr><tr><td></td><td>B (SE)</td><td>p-value</td><td>B (SE)</td><... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.